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Abstract 
GSK3β regulates Epithelial-Mesenchymal-Transition and Cancer Stem Cell properties 
and is a novel drug target for Triple-Negative Breast Cancer. 
Geraldine Vidhya Raja, MS. 
Advisory Professor: Sendurai Mani, Ph.D. 
Triple-Negative breast cancers (TNBCs) are highly aggressive and lack the expression of 
Estrogen Receptor (ER), Progesterone Receptor (PR) as well as Human Epidermal Growth 
Factor Receptor (HER2). Consequently, patients diagnosed with TNBCs have poor overall- and 
disease-free survival rates compared to other subtypes of breast cancer due to lack of targeted 
therapies as well as de novo or acquired chemoresistance, disease recurrence, and lack of 
targeted therapy. Hence it is critical to identify novel targets to treat TNBCs. TNBCs are 
characterized by the presence of mesenchymal-like cells, which is indicative that EMT (epithelial-
mesenchymal-transition) plays an important role in the progression of this disease. EMT has also 
been implicated in chemoresistance, tumor recurrence and generation of cancer stem cells 
(CSCs). The Wnt signaling pathway has been determined to be one of the major players in EMT 
and CSCs. Therefore, we analyzed patient survival data to determine a correlation between the 
expression of Wnt components and overall survival. Of the several possible players, higher 
expression of GSK3β correlated with poorer overall patient survival. In support of this observation, 
we identified a GSK3β inhibitor, BIO, in a drug screen as one of the most potent inhibitors of EMT. 
Since TNBCs are enriched with mesenchymal-like cells, we treated mesenchymal cell lines with 
the GSK3β inhibitors and found that GSK3β inhibitors were among the few drugs that could 
selectively kill mesenchymal-like TNBC cells compared to epithelial-like breast cancer cells. To 
determine if GSK3β inhibitors specifically target mesenchymal-like cells by affecting the CSC 
population, we employed the mammosphere assay and analyzed the CD44hi/24lo population of 
vii 
 
these cell lines.  We found that GSK3β inhibitors indeed decreased the CSC properties of the 
mesenchymal-like cell lines, and also decreased the expression of mesenchymal markers. 
Inhibition of GSK3β decreased the migratory properties suggesting that the inhibition of EMT by 
GSK3β inhibitor could contribute to the inhibitory effect of GSK3β on the migratory potential of the 
mesenchymal-like cells. Taken together, our studies demonstrate that GSK3β is a novel target 
for TNBCs and suggest that the GSK3β inhibitors could serve as selective inhibitors of EMT and 
CSC properties of the aggressive TNBCs, and may hence be ideal for combination treatment with 
standard-of-care drugs for women with this deadly disease. 
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Chapter 1 – TNBC and the potential role of EMT, CSCs and 
GSK3β. 
 
1A.  Introduction to Triple-Negative Breast Cancer (TNBC).  
Breast cancer is one of the leading causes of death among women and is second only to lung 
cancer. Breast cancer affects 1 in 8 women in the United States [1]. Breast cancers are 
molecularly classified into various subtypes. Primarily, breast cancers are classified based on the 
expression of Estrogen Receptor (ER), Progesterone Receptor (PR) and ERBB2 (HER2) using 
immunohistochemical analysis.  The Triple-Negative Breast Cancers (TNBCs) are breast cancers 
that do not express elevated levels of ER, PR or HER2 genes. TNBCs account for 15-20% of the 
newly diagnosed breast cancer cases. Most of the TNBCs are diagnosed in young patients and 
the disease is at an advanced stage by the time it is diagnosed [2]. TNBC tumors are usually 
larger in size, are of higher grade, and have lymph node involvement at the time of diagnosis [3]. 
Immunohistochemically, there is no specific marker to pinpoint a TNBC, rather the diagnosis of 
TNBC depends on the absence of the known markers, ER, PR and HER2.  
 
An additional level of complexity that accompanies TNBCs, is the presence of intra-tumoral and 
inter-patient heterogeneity [4]. TNBCs carry about 1.68 mutations per mega base of coding 
regions which is approximately 60 mutations per tumor [4, 5]. With that being said, the mutation 
burden is not uniform throughout the tumor and this is often accompanied by copy number 
alterations in genes involved in several different pathways. Mutations are random events and 
therefore, no two patients have the same mutations. So while all the TNBCs have similar gene 
expression profile, there is high inter-patient heterogeneity. The genetic composition of the tumors 
and thus their response to treatment is completely different from one patient to another. 
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TNBCs are classified as a single subtype, but the emergence of molecular profiling and other 
“omics” technologies have shown a large amount of heterogeneity among these tumors. Of these 
different breast cancer subtypes, the basal-like cancers mostly overlap with  the TNBCs, but 
despite the overlap are not synonymous [2]. The term basal-like indicates that these cancer cells 
express genes like KRT5, KRT14 and KRT17 and EGFR that are normally expressed by normal 
basal or myoepithelial cells [4]. More than 90% of basal-like breast cancers are TNBCs. Though 
basal-like tumors have a high level of heterogeneity, they have distinct molecular characteristics 
compared to other TNBCs [4]. In order to investigate the heterogeneity that exists in TNBC, the 
histopathological characteristics and gene expression profiles of 97 TNBCs were analyzed and it 
was found that the hierarchical cluster analysis also showed the presence of five distinct 
subgroups [2, 6-8]. Another group investigated the gene expression profiles of 587 TNBCs. In 
these analyses 6 different TNBC subtypes were identified: 2 basal-like-related subgroup (basal-
like 1 (BL1) and basal-like 2 (BL2)), 2 mesenchymal-related subgroups (mesenchymal (M) and 
mesenchymal stem-like (MSL)), one immunomodulatory subgroup (IM) and luminal androgen 
receptor group (LAR) [3, 4, 9] (Figure 1).  
In summary, TNBCs are highly aggressive breast cancers that have lower overall and disease 
free survival rates as compared to the other types of cancer. The main reasons for the lower 
survival rates are – absence of targeted therapy, tumor recurrence and chemoresistance, and 
metastasis. 
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1A.a. Absence of targeted therapy for TNBC 
Patients with TNBCs have relatively poorer prognosis as compared to other subtypes of breast 
cancer. Currently chemotherapy is the only treatment option that is available for patients with 
TNBCs irrespective of their stage [4], due to the  lack of targeted treatment. [4]. As previously 
mentioned, TNBC tumors do not express ER, PR or HER2 genes, all of which are molecular 
targets of therapeutic agents used to treat breast cancer. Due to the extensive genetic and 
molecular profiling studies several different targetable mutations have been identified [4]. In 
addition to the mutations in P53 and PIK3CA gene, other actionable targets such as deletions of 
PTEN or INPP4B genes and amplifications such as KRAS, BRAF, EGFR, FGFR1, FGFR2, 
IGFR1, KIT and MET have been identified [4]. However, the actionability of these targets is yet to 
be established because each tumor has multiple mutations which play major roles in several vital 
intertwined pathways, thus making it difficult to predict the outcome of targeting these mutations. 
Additionally, due to the intra-tumoral heterogeneity within TNBCs, a target that may affect one 
Triple Negative 
Breast Cancer
Basal-like
Immunomod
ulatory (IM)
Mesenchymal 
(M)
Basal-like 
1
Basal-like 
2
Mesenchymal 
stem-like (MSL)
Luminal Androgen 
Receptor
Figure 1 – Classification of triple negative breast cancers (TNBCs). TNBCs are breast
cancers that lack the expression of ER, PR, and HER2. TNBCs can be subdivided into
Luminal Androgen Receptor (LAR), Basal-like (Basal-like 1 and Basal-like 2),
Immunomodulatory, Mesenchymal, and Mesenchymal stem-like subtypes.
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clonal population may not affect another clonal population thus giving rise to chemoresistance or 
lack of response to targeted therapies. 
 
1A.b. Contribution of tumor relapse and chemoresistance to TNBC-related fatality 
In addition to lack of targeted therapy, the factor that increases the lethality of the TNBCs is the 
risk of tumor recurrence and emergence of chemoresistance. Extensive research has rendered 
breast cancers curable as long as it is discovered at an early stage. However, many a times the 
disease-free survival is disrupted by the reappearance of the tumor at the primary or a secondary 
site. Recurrence is one of the major reasons for breast cancer-related fatalities [10, 11]. The rate 
of recurrence of breast cancer is estimated to be 15-20% [12, 13]. Of these, 60-80% of tumor 
recurrences occur within 3 years, but the chances of recurrence exist up to 20 years after the 
diagnosis of the disease [9]. Therefore several studies have been undertaken to discover a 
predictor or pattern that might indicate the probability of recurrence and thus aid in preventing the 
relapse of the disease [10].  
 
In an effort to predict recurrence, the correlation between subtype of tumor and the disease 
relapse has been examined. It has been observed that the rate of recurrence is higher for the ER-
negative subtype of breast cancer in the first 5 years following the diagnosis and treatment [10, 
14]. As discussed earlier, the aggressive TNBCs have a higher rate of recurrence both at the 
primary and secondary site as compared to tumors that are ER-positive. It was also found that 
the ER+ and PR+ patient had lower rate of tumor recurrence as compared to TNBCs [10, 15]. 
These studies indicate the importance of molecular classification of tumors in the clinics both for 
the treatment and for taking preventive measures. 
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There are mainly 2 hypotheses to explain tumor recurrence. The first hypothesis is that the 
recurrence exists before the primary diagnosis and may have been detected as a multifocal tumor. 
The second hypothesis is the wound oncogene wound healing (WOWH) hypothesis [10, 16]. The 
WOWH hypothesis proposes that there is an intricate link between stress and oncogenesis. The 
stress could be either physical like radiation, chemical, like carcinogens or biological like 
inflammation, trauma, presence of pre-cancerous lesions, oncogenes and the progression of 
cancer [16]. When a tumor is diagnosed and treated, the region of treatment is damaged and 
faces a harsh environment followed by inflammation [10, 16]. This could in turn aggravate an 
existing injured cell to undergo transformation or injure new cells and create a new wound. Thus, 
depending on the presence of a pre-existing wound or creation of a new wound and the different 
insults weathered by the body in question, the tumor recurs [10, 16].  
 
The causes of breast cancer recurrence are still unknown but following are the molecular factors 
which have been found to contribute to the tumor recurrence including epithelial-mesenchymal-
transition (EMT), cancer stem cells (CSCs), Wnt signaling, circulating tumor cells (CTCs) and few 
other factors such as β1 Integrin, notch signaling, hedgehog signaling, and miRNAs [12]. Until a 
clear insight is gained into the mechanism of breast cancer recurrence, it would be impossible to 
develop targeted therapies to prevent breast cancer recurrence. However, few drugs such as 
bisphosphonates and aromatase inhibitors and natural compounds such as curcumin, 
sulforaphane, isoflavones, EGCG and resveratrol are being investigated for their potency in 
preventing breast cancer recurrences [10, 17].  
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1B. TNBCs are highly metastatic  
As mentioned above, metastasis and not the primary tumor is the principle cause of cancer-
related fatalities. More than 90% of cancer-related deaths are due to the metastasis and therefore 
it is imperative that we find a means of disrupting or reverting this lethal process [18, 19]. 
Metastasis is a cascade of steps in which cancer cells from the primary tumor dissociate, invade 
the surrounding connective tissue and intravasate into the vasculature to enter circulation. These 
tumor cells, now called the circulating tumor cells (CTCs), find anchor on the endothelium and 
extravasate to enter the secondary site where they form micrometastases. These subsequently 
establish a favorable niche where they proliferate to form macrometastases which is what is 
detected as the metastatic lesion [20]. Usually, these metastatic lesions are formed in vital organs 
or regions that are difficult to surgically resect thus further endangering the life of the patient. 
TNBCs have 4 times more the tendency to metastasize to the visceral organs as compared to the 
other subtypes of breast cancers [21, 22]. Each step of the metastatic cascade is essential for the 
cells to successfully metastasize and the ability of the cell to complete each of these steps 
determines its metastatic potential. Therefore each step serves as an opportunity to impede and 
halt the process. Understanding these processes in depth is vital for reducing the metastatic 
potential of the cancer cells. The steps of the metastatic cascade are as follows; 
Invasion - Normally, the tumor is comprised of epithelial cells that have polarity and a basement 
membrane along with providing the architectural support also provides signaling molecules that 
help the cells determine and retain their polarity [18, 23]. When the cells try to break free from the 
bonds and polarity, the signaling and the basement membrane serve as a barrier [18]. In the 
mammary gland, the myoepithelial cells and the alterations in the stiffness of the connective tissue 
and several other factors serve as a deterrent for the invasion of the basement membrane [18, 
24, 25].  The invading cancer cells might utilize either the EMT-mediated mesenchymal program 
or the amoeboid invasion program [18, 26]. The induction of EMT results in the loosening of the 
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cell-cell bonds and also enhances the secretion of matrix metalloproteases (MMPs) and other 
enzymes that aid in the breakdown of the basement membrane and the connective tissue limiting 
the tumor mass. Once the cells have breached the basement membrane, they come in contact 
with the stroma. The tumor-associated stroma may be inflamed or trying to heal the wound and 
depending on the state of the stroma might contain fibroblasts, endothelial cells, mesenchymal 
stem cells, adipocytes and immune cells. This creates a positive feedback loop where the 
invading tumor cells condition the stroma to aid in metastasis and the inflamed stroma promotes 
invasion of the cancer cells. TNBCs are associated with the presence of invasive edges and the 
presence of lymphocytic infiltrates at these edges [27]. 
 
Intravasation – Intravasation is a process, where the cancer cells leave the primary site and 
enter the 2 main circulatory systems of our body, the lymphatic system and the vasculature [18]. 
While the cells that enter the lymphatic system mostly serve for diagnostic purposes, the cells 
that enter the vascular circulation are the ones that are primed to metastasize to a secondary 
distant location [18, 19]. When the tumor cells intravasate, they and the assisting stromal and 
immune cells secrete molecules such as transforming growth factor-β (TGFβ), Epidermal growth 
factor (EGF) and colony-stimulating factor-1 (CSF-1) that alter the pericytes and weaken the 
trans-endothelial barrier and allow the cells to invade [18, 28]. The other mechanism is the 
formation of new blood vessels. As the tumors grow in size, they secrete vascular endothelial 
growth factor (VEGF), MMP-1 and 2, cyclooxygenase-2 (COX2), epiregulin (EREG) that stimulate 
the formation of new blood vessels that serve to supply oxygen and nutrition to the growing tumor 
[29]. However, this neoangiogenesis leads to the formation of leaky vasculature due to weak 
endothelial interactions and lack of pericytes which allows the entrance of the tumor cells into 
circulation [18, 30]. 
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Circulation – Once the cancer cells intravasate and enter into circulation, they are known as 
circulating tumor cells or CTCs. These tumor cells have to survive in the circulation. The first 
major challenge is that capillaries are smaller in diameter than the tumor cells and this results in 
CTCs getting trapped in capillaries [18]. The next challenge faced by them is the onset of anoikis. 
Normal cells are anchorage dependent and when disconnected from the extracellular matrix, 
anoikis sets in and leads to cell death. However, CTCs avoid anoikis by metabolic reprogramming 
and upregulating suppressors of anoikis like Tropomyosin receptor kinase B (TrkB) [31-33]. 
Another theory proposed is that several of the CTCs get trapped in capillaries or exit circulation 
and extravasate before anoikis could be triggered in cells [18]. The other challenges that the CTCs 
face are the circulating immune cells and the hemodynamic shear that can lead to the disruption 
of the cell. In order to overcome these, the CTCs have been found to attach to platelets in 
circulation and form large emboli that cannot be detected by the immune cells and to tolerate the 
shear force [34].  
 
Extravasation – The CTCs that survive the circulation and get trapped in the capillary beds at 
different locations have to enter back into the tissues in order to form metastatic lesions. There 
are mainly 2 ways in which this is achieved. The trapped cells can proliferate and form colonies 
and these colonies then secrete factors that can help break down the endothelial barrier and 
provide access to the secondary site of metastasis. The primary tumor cells and the CTCs 
themselves secrete factors such as angiopoietin-like-4 (Angptl4), EREG, MMPs, VEGF etc. that 
increase the permeability of the vasculature [35]. Additionally, certain immune cells such as 
inflammatory monocytes have been known to enhance extravasation of breast cancer cells into 
the lungs [36].  
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Micrometastasis – The cells that have extravasated have to then adapt to the new 
microenvironment which is usually different from that of the primary site. However, it has been 
observed that the micrometastatic niche is primed before the arrival of the cancer cells to the 
metastatic site [37]. The primary tumor has been found to secrete factors which include Lysyl 
Oxidase (LOX) [37]. LOX stimulates the production of fibronectin which in turn attracts VEGF 
receptor-positive hematopoietic progenitor cells [37, 38]. These cells secrete MMPs which breaks 
down the ECM at the site of future metastasis. The breakdown of the ECM is accompanied by 
the release of chemoattractants such as stromal cell derived factor 1 (SDF-1) [37]. While these 
priming processes take place at the site of metastasis, the homing tumor cells also make 
alterations in their signaling to adapt to the new environment. Breast cancer cells that form 
micrometastasis in the bone have been observed to activate Src signaling and this promotes cell 
viability in the bone microenvironment without affecting the homing capacity of these cells. While 
suppressing Src signaling decreased metastatic lesions in the bone, it did not prevent the same 
breast carcinoma cells from colonizing the lungs [18, 39].  
 
Macrometastasis – Macrometastasis is a process in which the micrometastatic colonies 
proliferate to form diagnosable colonies. Not all the micrometastatic colonies form 
macrometastasis. The unfavorable microenvironment can serve as a deterrent for the growth of 
these colonies. Many of these colonies either die slowly over a long period to time due to lack of 
favorable stimuli or remain dormant and just stay viable such that there is no alteration in the cell 
number. In the case of breast cancer, it has been observed that cells that are unable to stimulate 
Focal Adhesion Kinase (FAK), integrin β1 and Src pathways are unsuccessful in forming 
metastatic colonies [40-42]. Additionally, absence of stimulating factors in the microenvironment 
could also contribute to this quiescence. However, some of the factors secreted by the primary 
tumors may serve as stimulants for the dormant metastatic colonies [43, 44]. 
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Another reason for the inability of the micrometastatic colonies to grow into macrometastases is 
the low proliferative rate of these cells as compared to the high apoptotic potential of these cells. 
This has been attributed to the lack of neoangiogenesis in these lesions as a result of which they 
are deprived of both oxygen and nutrition [45]. One of the means of overcoming these barriers, is 
by the induction of EMT. As mentioned previously, the cells that have undergone EMT gain stem-
like properties which enable them to have immense proliferative and self-renewing potential which 
aids these cells in the micrometastatic colonies to proliferate and form macrometastatic colonies.  
 
Another factor that determines the ability of the cells to colonize and form metastatic lesions is 
their ability to turn on the genes required to make them compatible with the microenvironment at 
the metastatic site. This fact was discovered by Paget when he put forward the seed and soil 
hypothesis [46]. Not all the cancer cells can survive in all the microenvironments that they home 
to. Only the ones that are capable of adapting to the new microenvironment survive and colonize 
the secondary metastatic site. As a proof of this concept, it has been observed that the genetic 
and epigenetic profile of the breast cancer cells that metastasize to the bone is dramatically 
different from that of the cells metastasizing to the brain, lung or liver [47-50]. However, the genetic 
and epigenetic profile is not determined by the destinated organ alone. For example, the genetic 
and epigenetic makeup of the breast cancer cells colonizing the bone is very different from the 
profile of prostate cancer cells which metastasize to the bone [18].  
 
Due to the high complexity of this cascade, only very few of the cells that are disseminated from 
the primary tumor actually reach their target and establish macrometastasis. It is these few cells 
that need to be targeted and inhibited from successfully completing this cascade. One of the 
crucial events that enhances the metastatic potential of the cancer cells is the process of EMT. 
Hence, understanding and targeting EMT is essential to inhibit metastasis. In summary, TNBCs 
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are highly aggressive subtype of breast cancers. This tumor subtype has high similarity to basal-
like breast cancers. Due to the absence of targeted therapy, TNBCs are difficult to retreat. These 
tumors predominantly develop resistance to chemotherapy also develop metastasis at high rate. 
As these tumors are highly enriched for cells with EMT/CSC properties, targeting EMT may be a 
potential means of inhibiting TNBCs. 
 
1C. Epithelial-Mesenchymal-Transition is a vital player in the chemoresistance, 
tumor relapse and metastasis of TNBCs. 
Epithelial-mesenchymal-transition is a dynamic process that was initially discovered by 
Dr.Elizabeth Hay in 1980 [51, 52]. She observed a phenomenon in which the epithelial cells 
acquire mesenchymal properties in the primitive streak of a chick embryo and named it                                                                                                             
mesenchymal transformation [51, 52]. This process was later renamed as the epithelial- 
mesenchymal-transition to reflect its transient nature [52]. During the process of EMT, an 
epithelial cell which is normally attached to the basement membrane in an apical-basal 
orientation, gains mesenchymal characteristics such as a spindle-shaped morphology, increased 
migratory and invasive potential, resistance to apoptosis and senescence and expresses 
significantly greater amount extra-cellular matrix genes [52, 53] (Figure 2). EMT is a well-
established central player in embryonic development, wound healing and tumor progression and 
as a result a lot of effort has been devoted to unraveling the mechanism and regulation of EMT. 
In breast cancer, circulating tumor cells (CTCs) isolated from peripheral blood of patients, share 
several properties with mesenchymal cells indicating that these cells have undergone EMT [53-
55]. Furthermore, basal-like and claudin-low breast cancers are transcriptionally similar to 
mesenchymal cells [56-58].  
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EMT is also closely linked to cancer stem cells (CSCs) [59]. Cancer stem cells are cells that have 
unlimited self-renewal potential and are capable of giving rise to both undifferentiated and 
differentiated daughter cells. FOXC2, a transcription factor was demonstrated to be an important 
EMT marker as well as an indicator of CSC properties, thus suggesting the EMT and CSCs are 
intricately linked [59, 60].  
 
 All these changes effected by EMT involve a complex cascade of signaling that orchestrates this 
smooth transition. Several transcription factors, cell surface markers, cytoskeletal organization 
proteins, and micro-RNAs (miRs) play a pivotal role in choreographing this intricate process. 
Epithelial Properties
• Cobble-stone morphology
• Tight cell-cell adhesion
• Differentiated
• Less Invasive 
Mesenchymal Properties
• Spindle Shaped
• Loss of cell-cell adhesion
• Less differentiated
• Highly invasive
• Cancer stem cell properties 
EMT
Figure 2 – Epithelial to mesenchymal transition (EMT). EMT is the process that induces the
phenotypic alteration of epithelial cells to mesenchymal cells as a result of which they gain
enhanced migratory potential and stem-like properties listed above, which aids in the
metastatic cascade.
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However, this signaling can be inhibited or reversed which in turn induces the process known as 
the mesenchymal-epithelial-transition or MET [52]. This ability of the cells to switch back and forth 
between the epithelial and the mesenchymal phenotype is known as plasticity [52]. The presence 
of this plasticity in TNBCs enhances their metastatic potential. Understanding the regulation of 
EMT will facilitate the identification of regulatory nodes that can be targeted to inhibit metastasis 
of TNBCs. 
 
1C.a. Regulation of EMT 
Induction of EMT is accompanied by an alteration in gene expression in order to help the cells 
gain mesenchymal properties. However, these changes in the gene expression are not uniform 
and differ depending on the factor inducing EMT and the tissue in which the transition is taking 
place. While the post-translational modifications disrupt epithelial cell adhesions and polarity, the 
presence of the epithelial cell adhesion molecules will promote re-assembly of these adhesions. 
Therefore, in order to prevent de novo formation of epithelial cell adhesions and acquisition of 
polarity, the transcription of these molecules have to inhibited and replaced with molecules that 
form mesenchymal adhesions. E-cadherin is repressed in all cells undergoing EMT regardless of 
the cell type or the EMT-inducing factor [51]. During the cadherin switch, which is considered to 
be one of the hallmarks of EMT, the expression of N-cadherin is upregulated [53, 61]. N-cadherin 
connects to the actin cytoskeleton via β-catenin and α-catenin, forms homotypic interactions with 
other mesenchymal cells which facilitates migration, and interacts with receptor tyrosine kinases 
such as PDGF and FGF receptors [62-64].  
 
The composition of the extracellular matrix also undergoes a dramatic change. There is increased 
expression of mesenchymal ECM molecules such as vimentin and fibronectin and decrease in 
the expression of epithelial ECM molecules such as keratins [65]. Additionally, the expression of 
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cellular molecules that interact with the ECM is also altered. To choreograph this transition, 
several different transcription factors, non-coding RNAs, alternative splicing, composition of the 
microenvironment, ligands and growth factors contribute to ensure the effective switch from the 
epithelial to the mesenchymal phenotype.  
 
There are several transcription factors that are potent inducers of EMT. The mechanism by which 
they induce EMT has been well-studied and established. Some of the most well-studied 
transcription factors that regulate EMT include Snail, Slug, Zeb1, Twist and FOXC2 [51, 60, 66, 
67]. The Snail family of transcription factors is made up of 2 sub-families, the Snail family that 
includes Snail and Slug and the other sub-family is Scratch [51, 68, 69]. Of these different Snail 
family members, only Snail and Slug have been implicated in EMT and therefore in development, 
fibrosis and cancer [51].  
 
Numerous EMT inducers such as TGFβ, Wnt, Notch and receptor tyrosine kinases activate the 
expression of Snail [51, 66]. Snail induces the mesenchymal phenotype by the repression of E-
cadherin. Snail binds to the E-cadherin promoter and recruits epigenetic modifier, Polycomb 
Repressive Complex II (PRC2) which comprises methyltransferase enhancer of Zeste homologue 
2 (EZH2), G9a and suppressor of variegation 3-9 homologue 1 (SUV39H1), the co-repressor 
SIN3A, histone deacetylases 1, 2, and 3 and Lys-specific demethylase 1 (LSD1) [70-75]. All these 
components of the complex work together to ensure the epigenetic inhibition of E-cadherin [51]. 
Snail also induces the expression of mesenchymal markers such as fibronectin, N-cadherin, 
collagen, MMPs, Twist and Zeb1 [51]. 
 
15 
 
One of the primary regulators of Snail is glycogen synthase kinase 3 β (GSK3β) [76]. GSK3β is a 
multifaceted serine threonine kinase that has regulatory functions in several vital cellular 
processes such as cell cycle, apoptosis, migration, metabolism etc. [77]. Several signaling 
pathways regulate Snail function via their effect on GSK3β. The Wnt, Notch, NFkB and AKT-PI3K 
signaling pathways inhibit GSK3β thereby promoting the function of Snail [51, 78-80]. 
Phosphorylation of Snail by (small C-terminal domain phosphatase 1) SCP1 interferes with the 
ability of GSK3β to phosphorylate Snail thereby stabilizing it [51, 81]. Phosphorylation by p21 
Activated Kinase 1 (PAK1) and Large Tumor Suppressor 2 (LATS2) promotes nuclear localization 
of Snail [82, 83]. The players that negatively regulate Snail include (Protein Kinase D1) PKD1 and 
p53, which promote the nuclear export, and the ubiquitination and degradation of Snail 
respectively [51, 84]. 
 
Along with Snail, Zeb1 is also a potent inducer of EMT [66]. Zeb1 recognizes the E-Box for 
binding. It can act both as an activator and as a repressor depending on the co-factor present [51, 
66]. Zeb1 represses the expression of E-cadherin in the presence of the co-repressor 
Switch/sucrose nonfermentable (SWI/SNF) chromatin remodeling protein BRG1 rather than in the 
presence of its usual co-repressor, the C-terminal binding protein (CTBP) [85]. Zeb1 expression 
is upregulated during EMT by Snail or by the activity of ligands such as TGFβ and Wnt [86]. The 
expression of Zeb1 is also regulated by miR200 which is associated with the epithelial phenotype 
[87]. 
 
The other transcription factors influencing the process of EMT include the bHLH transcription 
factors, the FOX family and the GATA family of transcription factors. FOXC2 is one of the 
transcription factors that has been reported to be upregulated following EMT regardless of the 
pathway via which EMT is induced [60]. Additionally, inhibition of FOXC2 is sufficient to inhibit 
EMT induced by potent EMT inducers such as Snail, Twist, Goosecoid and TGFβ [60]. 
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Overexpression of FOXC2 has been shown to induce EMT in human mammary epithelial (HMLE) 
cells and FOXC2 has been shown to be responsible for the CSC properties of the cells that have 
undergone EMT [60, 88, 89]. Of the several members of the bHLH transcription factor family, E12, 
E47, Twist 1, Twist 2 and inhibitor of differentiation (ID) have been shown to play a role in EMT 
[66]. As tumors progress and grow, certain regions undergo hypoxia, which turns on the 
expression of HIF1α which transcriptionally upregulates the expression of Twist and induces EMT 
in the tumor. The next layer of regulation of Twist depends on the interacting proteins. Twist 
functions as a dimer and can form homo- or heterodimers with E12, E47 or ID. Dimerization with 
ID inhibits Twist function and therefore ID needs to be repressed for the effective functioning of 
Twist [90]. TGFβ can cause repression of ID thus promoting the transcriptional activity of Twist 
[91]. Twist is also capable of recruiting epigenetic modifiers to the promoter regions of its target 
genes and modifying their expression. Twist is capable of repressing the expression of E-cadherin 
in multiple ways independent of Snail [86, 92, 93]. The other transcription factors involved in the 
induction of EMT includes members of the forkhead box (FOX), GATA and Sry box (SOX) 
transcription factors [94, 95]. 
 
Next to transcription factors, the growth factors are most frequently studied in association with 
EMT. Several growth factors including, EGF, FGF, HGF, IGF, PDGF, TGFβ, and Wnt have been 
examined for their effect on EMT. Fibroblast growth factor (FGF) induces EMT in epithelial cells 
by upregulating the expression of Slug, α2β1 integrin, and MMP13 and by destabilizing the 
desmosomes [96, 97]. Hepatocyte growth factor (HGF) binds and activates the c-Met receptor 
which is also known as the HGF receptor (HGFR). HGF was identified as a “scatter factor” due to 
its ability to transform kidney epithelial cells to fibroblast-like motile cells. HGF induces EMT by 
stimulating the expression of Snail or Slug depending on the type of cell and requires the activity 
of ERK-MAPK pathway [98]. HGF also represses the expression of desmoplakin which in turn 
destabilizes the desmosomes [99]. In certain breast cancer cells, Insulin-like growth factor 1 
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(IGF1) has been observed to induce EMT, which is characterized by an increase in the expression 
of N-Cadherin, vimentin and fibronectin and decrease in the expression of E-cadherin [100]. The 
Snail-NFκB signaling pathway is activated in these breast cancer cells [100]. The IGF receptor 
(IGFR) interacts with E-cadherin to form a complex which is disrupted upon activation of the 
receptor by the ligand IGF1 [101]. This disruption of the E-cadherin IGFR complex enhances the 
motility of the cells. However, the response elicited by IGF1 is not the same in all the cell types. 
In other cell lines, IGF1 was seen to upregulate the expression of Zeb1 in a PI3K and MAPK 
dependent manner [102]. Epidermal growth factor (EGF) is another growth factor that has been 
known to induce EMT in breast cancer cells. Exposure to EGF leads to the endocytosis of E-
cadherin and upregulation of Snail and Twist [103]. MMPs are upregulated and the ERK-MAPK 
pathway is activated in breast cancer cells that have been exposed to EGF [104]. Platelet-derived 
growth factor (PDGF) induces EMT by stimulating the nuclear localization of β-catenin and 
repression of E-cadherin [105].  
 
TGFβ family of ligands consists of 3 TGFβ ligands, 2 activins, bone morphogenetic proteins 
(BMPs) and several other ligands [106]. TGFβ3 has been implicated in the induction of EMT 
during development whereas TGFβ1 has been attributed with the role of inducing EMT during 
wound healing, in cancer and fibrosis and also in endothelial-mesenchymal-transition (EndMT) 
[107-111]. 
 
TGFβ ligands bind to tetrameric transmembrane receptors to activate TGFβ signaling [112]. When 
the ligand binds to the receptor containing TGFβRII, it phosphorylates and activates TGFβRI 
which turns on SMAD signaling by phosphorylation of the C-termini [113]. Activated SMAD2 
and/or 3 interact with activated SMAD4 to form a trimer which translocates to the nucleus to alter 
the transcription of mesenchymal genes such as fibronectin and collagen αI [112]. Depending on 
the other SMADs that are activated, SMAD4 can bind to SMAD1 or SMAD5. If the inhibitory 
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SMAD6 or 7 bind to the receptors, the TGFβ signaling is interrupted [114]. Thus the activation of 
the TGFβ signaling involves a delicate interplay of ligands binding to the receptors and the 
presence of the appropriate SMADs to relay the signal. In addition to spurring EMT by promoting 
the transcription of the target genes, the components of the TGFβ pathway also indirectly aid the 
function of other EMT inducers. For example, Snail in the presence of SMAD3 upregulates the 
transcription of its target genes whereas the expression of Slug is indirectly upregulated by the 
SMAD3 mediated increase in the expression of myocardin-related transcription factor (MRTF) 
which transcribes Slug [115]. SMAD3/4 complex can bind and regulate the transcriptional activity 
of the Zeb1 transcription factor [116]. They also interact with activating transcription factor 3 
(ATF3), which enables the repression of ID, facilitating the activity of Twist. Additionally, they can 
also upregulate the expression of HMGA2 [116]. 
 
TGFβ also functions independently of SMADS to promote EMT. The TGFβ receptor interacts with 
and phosphorylates partition defective (PAR6), which is an integral part of the tight junction 
responsible for maintaining the cell polarity [117]. This aids in dissolving the junction which is one 
of the very first steps in early EMT. It also plays a role in activating the RHO pathway which 
enhances cell mobility by facilitating the formation of lamellipodia and filopodia [118]. The 
activation of the PI3K-AKT pathway is essential for the TGFβ induced EMT to such an extent that 
inhibiting PI3K prevents the induction of TGFβ mediated EMT [119]. TGFβ induces Akt-mediated 
phosphorylation of heterogeneous nuclear ribonucleoprotein E1 (hnRNPE1), which releases it 
from the 3’ untranslated region of disabled 2 (DAB2) and interleukin (IL) like EMT inducer (ILEI) 
mRNA, which allows their translation and promotes EMT [120]. The BMPs play a role in both EMT 
and MET and of the many BMPs, BMP 2, 4 and 7 promote EMT [121, 122]. Like the TGFβ 
signaling pathway, the Wnt signaling pathway is one of the well-studied pathways that plays an 
important role in development and EMT [123, 124].  
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1C.b. Wnt signaling has been implicated in EMT and CSC enriched TNBCs. 
The Wnt signaling pathway is one of the well-studied pathways that play an important role in 
development and disease [123, 124]. The Wnt signaling pathway is named after the Wnt1 gene, 
homolog of Wingless gene in flies, which was shown to regulate polarity during development. 
There are 19 Wnt genes in humans and most mammals, which are classified into 12 subfamilies 
[125]. All the Wnt genes encode for secreted cysteine-rich, 40kDa glycoproteins which share 
about 35-85% homology. Of these 19 Wnts, 7 ligands have been found to be expressed in mouse 
mammary tissue and Wnt 2, 3, 4, 5A, 7B, 10B, 13 and 14 are expressed in human mammary 
gland [125-127]. Due to their structural similarity, Wnt ligands are redundant in function. The Wnt 
ligands bind to a heterodimeric receptor. The cell surface receptor that binds the Wnt ligands is 
comprised of a seven transmembrane domain protein belonging to the Frizzled (Fzd) family and 
a LDL receptor-related protein (LRP 5/6) [124, 125]. There are at least 10 known Frizzled proteins 
in humans and any of these can bind to any of the Wnt ligands to activate the downstream 
signaling [124]. When Wnt binds to the cysteine-rich part of the Fzd’s extracellular domain, it 
forms a trimeric complex with Fzd and LRP which induces a conformational change in the 
cytoplasmic domain of LRP 5/6 [125].  Based on the downstream signaling, the Wnt pathway has 
been classified as the canonical or the non-canonical pathway [124, 125]. Of the 2 signaling 
pathways the canonical signaling pathway is relevant to our studies and hence is described in 
detail. 
 
The canonical Wnt signaling, also known as the Wnt/β-Catenin signaling is the most studied of 
the Wnt signaling pathways. β-Catenin has roles both in the cytoplasm and the nucleus of the 
cell. In the cytoplasm, it forms complexes with E-cadherin and other proteins involved in 
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maintaining cell-cell adhesion, thus aiding in the maintenance of tissue integrity [125]. In the 
nucleus, it acts as a regulator of transcription [125]. When the Wnt signaling is off or the Wnt 
ligand is absent, newly synthesized β-catenin is marked for destruction by the destruction 
complex. The destruction complex is made up of scaffolding proteins, adenomatous polyposis 
coli (APC) and Axin 1 or 2, and kinases casein kinase 1 (CK1) and glycogen synthase kinase 3β 
(GSK3β). β-catenin is sequentially phosphorylated by CK1 followed by GSK3β, which marks it for 
ubiquitination and ultimately for destruction by the proteasome. When Wnt signaling is activated, 
cytoplasmic changes in LRP5/6 promotes its binding to Axin in the destruction complex. Fzd on 
the other hand, binds to Disheveled (Dvl) which is an Axin-binding protein [124]. Both these 
actions together prevents the destruction of β-Catenin, which starts accumulating in the cytoplasm 
and enters the nucleus. When the Wnt signaling is inactive, TCF (T-cell factor) /Lef are bound by 
a co-repressor called Groucho, which prevents transcription of their target genes [124]. When 
Wnt is activated and β-catenin enters the nucleus, it displaces Groucho and facilitates the 
interaction of TCF/Lef with co-activators such as B-cell lymphoma 9/legless (BCL9/LGS) and 
Pygopus (pygo) and promotes the transcription of its target genes [124]. The target gene list for 
the Wnt/β-catenin pathway has been growing since the day it was discovered and some of the 
target genes such as cyclin D1 and c-myc have been identified as being tumor promoters [125].  
 
In TNBCs and basal-like breast cancer Wnt signaling, both canonical and non-canonical 
pathways, is commonly dysregulated and contributes to enhanced tumorigenesis and metastasis 
[128-130]. Dyregulation of Wnt in TNBC patients was found to be associated with poor prognosis 
and higher risk of developing lung and brain metastasis [128, 131, 132]. The aberrations in the 
Wnt signaling pathway is evident from the fact that β-catenin nuclear localization, enhanced levels 
of cyclin D1 in invasive TNBCs, and increased levels of DKK1, another Wnt/B-catenin target gene, 
are observed [124].  In the nucleus, BCL9, a co-factor that binds and promotes β-catenin has 
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been found to be upregulated in basal-like breast cancers, and LBH and SOX9 both of which are 
β-catenin targets have been reported to be upregulated as well [124]. Immunohistological studies 
have shown high levels of β-catenin to be present in either the cytoplasm and/or nucleus of breast 
cancer tissue. In some of these cases, the increase in the expression of β-catenin was also 
accompanied by elevated levels of cyclin D1, a β-catenin target, and this correlated with poor 
survival [133-135]. These findings are also supported by the fact that elevated levels of β-catenin 
protein were detected in tumor lysates using western blotting technique, and this served as a 
molecular confirmation of the immunohistological observations [134]. Non-canonical Wnt 
signaling has also been demonstrated to promote TNBC metastasis via the JNK pathway [128, 
136]. TNBCs are highly enriched for CSCs which contribute to their higher rate of relapse and 
chemoresistance and studies have shown that this effect can be attributed to the dyregulation of 
Wnt signaling pathways in these CSCs [137]. These finding emphasize the need to target the Wnt 
signaling pathway to inhibit EMT and CSC-mediated progression of TNBCs. Therefore, we 
assessed the clinical significance of several key players of the Wnt signaling pathway using the 
KMPlotter and our preliminary studies drew our attention to GSK3β which is a critical player not 
only in the Wnt signaling pathway but also several other vital pathways that play a pivotal role in 
governing and regulating the cells. Therefore we decided to take a deeper look into this ubiquitous 
and multifaceted kinase, GSK3β. 
 
1D. Role of Glycogen Synthase Kinase 3β in tumor progression 
Glycogen Synthase Kinase 3 (GSK3), ATP:Phosphotransferase E.C.2.7.1.37 is a serine 
threonine kinase belonging to the CMGC (Cyclin-Dependent Kinases (CDKs), Mitogen Activated 
Protein Kinases (MAPKs), Glycogen Synthase Kinases (GSKs), CDK-like Kinases (CLKs)) family 
of kinases [138]. Kinases are a family of enzymes that catalyze the transfer of phosphate group 
from adenosine triphosphate (ATP) to their target substrates [139]. Serine-threonine kinases 
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specifically transfer the phosphate group to either serine or threonine residue on the substrate 
[139]. This phosphorylation can in turn regulate the stability, localization and function of the 
substrate. 
 
GSK3 was first isolated from the rabbit skeletal muscle [139, 140]. GSK3 is a highly conserved 
kinase and orthologs of this kinase are expressed in plants, fungi, worms, flies, sea squirts, and 
all the vertebrates [138]. Even species as far apart as humans and flies have 90% similarity within 
the protein kinase domain [141]. GSK3 was first discovered for its ability to phosphorylate 
glycogen synthase, the rate-limiting enzyme in the glycogen synthesis pathway and hence the 
name glycogen synthase kinase [140]. At about the same time GSK3 was found to activate ATP-
Mg-dependent form of type-1 protein phosphatase (Factor A) [140].  GSK3 was first isolated as a 
complex with Factor A and was cloned based on partial peptide sequencing [142, 143]. Two 
different cDNAs were isolated from rat brain and these corresponded to GSK3 alpha (GSK3α) 
and GSK3 beta (GSK3β) [138, 143]. The 2 isozymes are coded on 2 different genes. GSK3α is 
coded on chromosome 7 in mouse and on chromosome 19 in human and has molecular weight 
of 51 kDa [143]. GSK3β, on the other hand, is coded on mouse chromosome 16 and human 
chromosome 3 and has a molecular weight 47 kDa [143]. Although they are coded on different 
genes, they have 98% similarity in the kinase domain but only 85% overall sequence homology 
[143]. GSK3α has an extended glycine rich, 63 residues N-terminal region that might act as a 
pseudosubstrate [138, 139]. Both the isoforms are conserved in most of the species except birds 
which seem to have evolutionarily lost the expression of GSK3α [138]. A third isoform of GSK3, 
GSK3β2 has been recently discovered to be expressed in the brain tissue [144, 145]. This splice 
isoform is generated due to splicing between the exon 8 and 9 of GSK3β and results in the 
introduction of 13 amino acids into the kinase domain of GSK3β [144, 145]. Though GSK3α and 
GSK3β are highly conserved and have high level of homology, they are not functionally 
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redundant. This was evident when the transgenic mouse, in which the exon 2 of GSK3β was 
selectively deleted, was embryonic lethal due to extensive hepatocyte apoptosis, even after 
having a fully functional GSK3α [139, 146]. Of the 3 isoforms, GSK3β is the well-studied isoform. 
GSK3β is made up of 2 major domains. The β-strand domain is present in the N-terminus 
spanning the amino acid residues 25-138 and the α helical domain occurs at the C-terminus from 
amino acid residue 139 to 343 [146, 147]. The ATP binding domain is present at the interface of 
the 2 major domains. Arg96, Arg180 and Lys205 form a small pocket that recognizes the priming 
phosphorylation present on the primed substrates of GSK3β [146, 147]. 
 
GSK3β is a ubiquitously expressed gene and both isoforms are expressed in all mammalian 
tissues. GSK3β is highly expressed in the brain, both in the neurons and the glia. The name is 
very misleading as GSK3β was soon discovered to be associated with innumerable cellular 
functions including metabolism, cell signaling, cellular transport, apoptosis, proliferation, gene 
transcription, protein synthesis, stem cell renewal and differentiation, circadian rhythm, axial 
orientation, patterning,  response to DNA damage and migration [139]. 
 
GSK3β is involved in innumerable pathways that regulate myriads of cellular functions and is 
therefore highly regulated. In fact GSK3β is regulated at multiple levels. GSK3β recognizes 
substrates that have been previously primed by other kinases. This adds to the selectivity of 
kinase activity of GSK3β toward a substrate. Usually, GSK3β recognizes the motif “S/T-X-X-X-
S/TP” where the S/TP stands for the primed phosphorylated residue on the substrate [148]. 
However, GSK3β is capable of binding and phosphorylating both primed and unprimed substrates 
in a context-dependent manner. The ability of GSK3β to bind unprimed substrates also make the 
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phosphorylation status of the S9 residue irrelevant to its function in relation to that particular 
substrate [148].   
 
Another major regulatory mechanism is the post translational modifications of the enzyme itself. 
GSK3β activity is regulated through phosphorylation by other kinases such as Akt, ERK, FYN, 
p38MAPK, PKA, PYK2, and Src and by phosphatases such as PP1 and PP2A [77, 148]. 
Phosphorylation of GSK3β on Ser9 residue (Ser21 for GSK3α) inactivates the kinase whereas 
the phosphorylation of Tyr216 within the activation loop, increases its kinase activity [149, 150]. 
However, this regulation by phosphorylation is not as simple or straight forward as it appears. The 
phosphorylation status of GSK3β on the Ser9 residue is in a constant state of oscillation between 
phosphorylated and unphosphorylated [148, 151]. The phosphorylated residue inhibits GSK3β 
function by binding to the pocket to which primed substrates bind. Therefore, this inhibitory effect 
also depends on the concentration of the primed substrate present [148]. When the concentration 
of the primed substrate increases, it displaces the phosphorylated S9 residue and the enzyme is 
rendered active again. Additionally, in order for the catalytic activity to take place both the major 
domains, the β-strand domain and the α-helical domains, must align into a catalytically active 
conformation to effectively bind appropriate substrates [148].  
 
The substrate specificity and availability of GSK3β is also dictated by the association of the kinase 
with different protein complexes. The association of GSK3β with the destruction complex is one 
of the well-studied ones [148]. About 10% of the GSK3β present in the cells is found to be bound 
to Axin. Axin, in the destruction complex, binds GSK3β, Casein Kinase 1 (CK1) and β-Catenin 
and this facilitates the phosphorylation of β-Catenin by GSK3β [148]. However, β-Catenin is not 
the only substrate that binds both Axin and GSK3β. Other substrates of GSK3β such as Smad3, 
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tuberous sclerosis complex 1 (TSC1)/ hamartin and TSC2/tuberin have also been found to bind 
to Axin and this binding facilitates their phosphorylation by GSK3β [148]. Other scaffolding 
proteins with which GSK3β forms complexes include but are not limited to 14-3-3 proteins, 
glycogen synthase kinase 3β interacting proteins (GSKIP), protein 4.1R and suppressor of fused 
(sufu) [148].  
  
 In addition to the above-mentioned means of regulation, GSK3β is also regulated by subcellular 
localization. GSK3β is present in 3 different pools, i.e. the mitochondrial pool, cytosolic pool, and 
nuclear pool [148]. The mitochondrial GSK3β could play a role in the regulation of apoptosis. It 
has been noted that during the induction of apoptosis, the active form of GSK3β is dramatically 
upregulated in the mitochondria [148, 152, 153]. However, much is yet to be discovered about 
the roles and regulation of mitochondrial pool of GSK3β. The nuclear pool of GSK3β is better 
studied as a major proportion of GSK3β substrates are transcription factors. Some of the 
transcription factors regulated by GSK3β include Fos/Jun, AP-1, CREB, heat shock factor 1, 
nuclear factor of activated T cells (NFAT), myc, C/EBP, NFκB, p53, and signal transducer and 
activator of transcription-3 (STAT3) [148, 154-156]. Interaction with FRAT protein facilitates 
nuclear export of GSK3β [157]. Recently, roles in epigenetic alterations have also been attributed 
to GSK3β.  Evidence indicates that GSK3β phosphorylates histones and promotes 
phosphorylation of histones by other kinases [158, 159]. In addition, GSK3β also has been shown 
to phosphorylate and either activate or inactivate HDACs and in turn HDACs alter the activity of 
GSK3β [160-163].  
 
Cytoplasmic pool of GSK3β is present in several compartments within the cytoplasm [148]. This 
pool of GSK3β is in a constant flux shuttling between different compartments [164]. The well-
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studied portion of cytoplasmic GSK3β is the one that is found in the destruction complex. This 
pool of GSK3β is often found to be compartmentalized in the endosomes [165]. It is important to 
understand that this compartmentalization plays a very important role in contextual signaling of 
GSK3β. For example, the endosomal compartmentalization of GSK3β associated with the 
destruction complex allows GSK3β to signal both in Wnt-dependent and Wnt independent 
pathways at the same time [165]. While facilitating the versatility of GSK3β, compartmentalization 
also adds another layer of complexity while targeting GSK3β. 
  
1E. Role of GSK3β in cellular processes vital to metastasis 
1E.a. Cell Cycle 
Cell cycle is a highly regulated process by which the cells replicate. Cell cycle mainly is divided 
into 4 phases – Gap1 (G1 phase), synthesis (S phase), gap 2 (G2 phase) and mitosis (M phase) 
[166]. This complex cycle is regulated by cyclins and cyclin dependent kinases (CDKs) which 
function together as complexes [166]. The CDKs are inactive kinases untill they form complexes 
with the appropriate cyclins and this complex can then bind and phosphorylate the substrates. 
The CDKs are ubiquitous but the levels of cyclins change dramatically depending on the phase 
of the cell cycle [166]. Thus the cyclins follow a predictable pattern of expression and degradation 
and this serves to regulate the cell cycle. For example, cyclin D is upregulated in the G1 phase 
and binds to CDK4/6 whereas cyclin E is upregulated later in the G1 phase and binds to CDK2 
and facilitates the transition from G1 to S phase [166]. There are several cyclins and several 
CDKs, and the binding partners are yet to be determined. However, of all the cyclins, cyclin D1 is 
highly altered in cancer [166, 167]. Cyclin D1 mRNA and protein levels are upregulated following 
a mitogenic signal and remains high untill the mitogenic signal persists. Cyclin D1 interacts with 
CDK4/6 to form a complex which is phosphorylated and activated by CDK activating kinase (CAK) 
[168] . The activated cyclin D1/CDK4/6 complex then acts as a sequestering protein to prevent 
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the interaction of CDK-inhibitory proteins from the cyclin E/CDK2 complex thus resulting in the 
accumulation of this complex. Cyclin E/CDK2 phosphorylates and inactivates Rb protein which 
acts as a gatekeeper protein by inhibiting its substrate E2F from transcribing its target gene such 
as cyclin E which is required for progressing to the next cell cycle phase [166]. When the cell 
enters the S phase, cyclin D1 is exported from the nucleus and is ubiquitinated and degraded by 
26S proteasome [166]. It is in regulating the degradation of cyclin D1 that GSK3β plays a vital 
role. Cyclin D1 is phosphorylated on threonine 286 by GSK3β [166]. This phosphorylation leads 
its interaction with CRM1 which facilitates the export of cyclin D1 to the cytoplasm for subsequent 
ubiquitination by SCF E3 ligase family and degradation [166]. Thus GSK3β is essential for the 
turnover of cyclin D1 which is necessary for the progression of the cell cycle. 
 
1E.b. Apoptosis 
Apoptosis or programmed cell death is a well-orchestrated process by which a cell undergoes 
self-destruction through a cascade of events. GSK3β has been demonstrated to play a very 
important role in the regulation of apoptosis [169]. GSK3β has been attributed with the induction 
of apoptosis following DNA damage, hypoxia and endoplasmic reticulum stress. It mainly brings 
about this effect by phosphorylating and inhibiting pro-survival proteins such as CREB, heat shock 
factor 1 and p53 [154, 169]. GSK3β phosphorylates the C-terminus of p53 at Ser-33 and facilitates 
its pro-apoptotic function [170, 171]. p53 is a short lived protein and phosphorylation by GSK3β 
facilitates other post-translational modifications that stabilize p53 [169]. GSK3β also promotes the 
transcription of p53 target genes and regulates its subcellular localization. Binding of GSK3β to 
p53 also alters GSK3β. In addition to this, GSK3β also phosphorylates and inhibits MDM3 which 
is an E3 ubiquitin ligase responsible for ubiquitination and subsequent degradation of p53 [169, 
172].  
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GSK3β also regulates the intrinsic mitochondrial apoptotic pathway. The intrinsic apoptotic 
pathway depends on the proportion of active anti-apoptotic Bcl-2, Bcl-XL, Bcl-w, Mcl1, and A1 and 
pro-apoptotic proteins Bax and Bim belonging to the Bcl-2 family of protein [169, 173, 174]. Bax 
sequesters the anti-apoptotic proteins and binds to the mitochondrial membrane that results in 
the disruption of the mitochondrial membrane and the release of cytochrome c which in turn 
triggers caspase cascade and apoptosis [169, 174, 175]. GSK3β is capable of phosphorylating 
and activating Bax and phosphorylating Mcl1 and inhibiting its function [169]. Though, a pro-
apoptotic function has been attributed to GSK3β, several studies have also highlighted the ability 
of GSK3β to inhibit apoptosis. Thus, the ability of GSK3β to induce apoptosis depends on 
substrate availability and its subcellular localization. 
 
1E.c. Migration 
Migratory potential of the cells is a major contributor to its metastatic potential. One of the means 
by which EMT promotes metastasis is by enhancing the migratory properties of the cancer cells. 
GSK3β has been reported to play a pivotal role in the migration of the cancer cells. There are 
three major means by which GSK3β influences the migratory capacity of the cancer cells. These 
mechanisms include regulation of the actin cytoskeleton dynamics, microtubule formation and the 
interaction of the cells with their extracellular matrix (reviewed in [176]). 
The actin cytoskeleton is mainly regulated by the Rho family of GTPases and of these Rac, which 
influences lamellipodia formation, and Cdc42, which induces filopodia formation, are the most 
studied members and control actin polymerization [176-178]. Rho is another member that is 
equally well-studied but contributes to the cellular contractility. The Rho family proteins are highly 
regulated by GTPases activating proteins (GAP) and p190 RhoGAP is one such protein that is 
capable of regulating the activity of Rho family members and is in turn regulated by several 
kinases including GSK3β [176, 179-181]. In p190A RhoGAP knockout fibroblasts, the actin 
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polymerization was highly dysregulated and this could be corrected by overexpressing wild-type 
p190A RhoGAP in these cells [176, 181]. However, the introduction of mutant p190A RhoGAP 
that lacked the phosphorylation site for GSK3β was not capable of restoring the actin 
polymerization to normalcy in the p190A RhoGAP -/- cells, indicating the importance of GSK3β in 
the actin polymerization process [176, 181]. Thus, GSK3β can regulate cell migration by activating 
Rho. It is important to note that p190A RhoGAP and not p190B RhoGAP is phosphorylated by 
GSK3β and therefore GSK3β only influences the Rho proteins regulated by p190A RhoGAP and 
not those influenced by p190B RhoGAP [176, 181]. GSK3β has also been reported to activate 
ADP-ribosylation factor 6 (Arf6) which plays crucial role in vesicle trafficking, membrane ruffling 
and lamellipodia formation [176, 182, 183]. GSK3β also activates Rac in several different cell 
models and enables the cells to migrate. Thus GSK3β positively regulated cell migration by 
exerting its influence on different factors controlling actin polymerization. 
 
While actin polymerization provides the force for the cellular migration, the microtubules influence 
the directionality of the movement. GSK3β has been reported to regulate several of the proteins 
that are involved in the microtubule dynamics such as microtubule motor protein, proteins in the 
microtubule organizing center (MTOC) and protein complexes at the plus ends of the microtubules 
[176, 184]. The microtubules also serve to deliver different proteins from one part of the cell to 
the other. Kinesins are proteins that are made of 2 heavy chains that bind the microtubule provide 
a motor functionality to the protein and 2 light chains that can bind to the proteins such as APC 
and focal adhesion dissociation factors [185, 186]. GSK3β is known to phosphorylate the kinesin 
light chain and facilitate the dissociation of the protein bound to the light chain at its destination 
site [176, 185]. This function of GSK3β plays a very important role in facilitating the cellular 
migration and dissociation of focal adhesion complexes.  
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A migrating cell is in constant contact with its extracellular matrix. These interactions serve to 
determine the direction of the movement and also serve as temporary anchors to facilitate the 
forward movement. Cell movement takes place by dissolution of the existing focal adhesion and 
formation of the new focal adhesion. Paxillin is a component of the focal adhesion complex that 
is regulated by several kinases such focal adhesion kinase (FAK), Src and GSK3β [187, 188]. 
Phosphorylation of paxillin by GSK3β allows for the formation and maturation of the focal 
adhesions [176, 189]. Thus GSK3β regulates both dissolution and formation of focal adhesions 
to facilitate cell motility and this is of note as the subcellular localization of GSK3β and the 
availability of the substrate dictates whether GSK3β functions to dissolve or form focal adhesions. 
 
In summary, GSK3β functions in diverse manners to facilitate the progression of cell cycle, 
promotes apoptosis and facilitates cellular migration. Thus the effect of inhibition of GSK3β is 
dependent on the cumulative effect of GSK3β on all the different cellular processes. Inhibition of 
GSK3β might stall the cell cycle and thereby decrease the proliferation of the cells while inhibiting 
apoptosis which is essential for inhibiting tumor progression. In addition to these effects inhibition 
of GSK3β is also going to inhibit the migratory potential of the cancer cell. Thus the effect of 
GSK3β inhibitor on a cancer depends on the cell type, the pool of GSK3β affected, the substrates 
available and the cellular processes predominantly affected. This proves that the role of GSK3β 
as a tumor promoter or suppressor is entirely context dependent. The most important observation 
from these studies is that GSK3β plays context dependent role in cancer and this is mediated 
both in a Wnt signaling dependent and Wnt signaling independent manner and as GSK3β plays 
different roles in different cancers, it is essential to understand the role of GSK3β in breast cancer. 
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1E.d. Contribution of GSK3β to breast cancer. 
Several studies have been conducted to delineate the role of GSK3β in breast cancer. GSK3β 
has multiple targets and regulates several key players in breast cancer progression. In breast 
cancer, hyperactivation of Wnt/β-catenin pathway is implicated as discussed above and GSK3β 
is a negative regulator of the Wnt signaling pathway. However, no mutations in GSK3β have been 
reported in breast cancers [190]. GSK3β is also associated with the induction of apoptosis in 
breast cancer. Exogenous overexpression of kinase dead GSK3β, which is presumed to function 
as an inhibitor of endogenous GSK3β, was observed to promote breast cancer [191, 192]. In 
MCF7 cell line, kinase dead GSK3β led to the emergence of chemoresistance to doxorubicin and 
decreased its sensitivity to tamoxifen as compared to the MCF7 cells overexpressing the wild-
type GSK3β [191, 193]. On the other hand, the same MCF7 cells overexpressing kinase dead 
GSK3β, which displayed decreased sensitivity to doxorubicin and tamoxifen, exhibited increased 
sensitivity to rapamycin as compared to the MCF7 cells overexpressing the wild type GSK3β [191, 
193]. Overexpression of constitutively active GSK3β increased chemosensitivity and induced cell 
cycle arrest both of which contributed to reduced tumorigenicity [191]. GSK3β inhibitor SB415286 
was shown to induce EMT in MCF10A cells [194]. GSK3β is known to inactivate NFκB, which is 
an activator of Snail, an EMT inducing transcription factor in epithelial cells [191, 194]. This study 
demonstrated that GSK3β inhibitor SB415286 induced EMT by activating NFκB which in turn 
activated Snail [191, 194]. GSK3β has also been shown to phosphorylate and regulate both Snail 
and Slug, by marking them for degradation [195, 196].  
 
While several studies indicate that GSK3β is a tumor suppressor in breast cancer, other studies 
contradict these findings. Studies have shown that GSK3β overexpression, detected by 
immunohistochemistry, correlates with poor prognosis [197]. Quintayo et.al, used the Edinburgh 
Breast Conservation series to study the correlation between GSK3β and disease prognosis in 
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these breast cancer patients [197]. The Edinburgh Breast Conservation Series consists of 1812 
patient samples along with the complete history of their treatment and outcomes collected 
between 1981 and 1998 [197]. Of these samples, only 1681 tissue blocks were available and 
were included in this study [197]. These were sectioned to create a tissue microarray, which was 
used for immunohistochemical staining for GSK3β, p-GSK3β as well as other markers, and the 
stained tissues were histoscored [197]. The patient samples were classified into high or low 
expressing tissues based on the median histoscores and their distant relapse-free survival was 
plotted [197]. Of the 1681 samples, about 70% of the samples were stained successfully and the 
analysis showed that the samples that had high staining of GSK3β had shorter distant relapse-
free survival, whereas no such correlation was observed in the case of p-GSK3β [197]. The 
increased expression of GSK3β also correlated with the presence of metastatic lesions in the 
lymph node [197]. Overexpression of GSK3β correlated with higher tumor grade and tumor size. 
These tumors also lacked ERα, PR, and were characterized by an increased proliferative potential 
[197].  
 
Small molecule studies have also highlighted the fact that GSK3β inhibitors can serve as 
therapeutic agents in breast cancer to overcome chemoresistance [198]. While GSK3β has been 
attributed with tumor suppressive qualities [199], experiments have demonstrated that inhibition 
of GSK3β is correlated with positive outcome in breast cancer. Clinical trials conducted with Eli 
Lily GSK3β inhibitor, LY2090314, have demonstrated that GSK3β inhibitors improved the efficacy 
of platinum drugs and the patients in whom stable disease was observed following treatment with 
LY2090314 included a breast cancer patient [200]. Therefore, GSK3β inhibitors could serve as 
novel therapeutic agents to treat breast cancers, either as a single agent or in combination with 
standard of care drugs to help overcome chemoresistance or prevent the relapse of the disease.  
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1F. GSK3β, EMT and cancer stem cells. 
GSK3β is a ubiquitous kinase regulating multiple signaling pathways and also playing an 
important role in EMT. While GSK3β was first discovered for its role in regulating metabolism, it 
gained much of its prominence as a key player in the Wnt/β-Catenin Signaling. Wnt is a well-
known promoter of stem cell properties and therefore GSK3β, an inhibitor of the Wnt signaling 
pathway is commonly recognized as an inhibitor of stem cell properties. However, GSK3β is a 
highly regulated kinase and therefore its role and function is dictated by the context in which it is 
studied. GSK3β influences EMT by regulating the key players of EMT such as Snail, Slug and β-
Catenin.  
 
GSK3β binds to and phosphorylates Snail [195]. The phosphorylation of Snail by GSK3β at a 
single site marks it for ubiquitination by β-Trcp and thereby for destruction [195]. Phosphorylation 
of a second site on Snail regulates its subcellular localization and results in the translocation of 
Snail from the nucleus to the cytoplasm [195]. Inhibition of GSK3β was observed to upregulate 
the expression of Snail and thereby inhibit the expression of E-cadherin, one of the most 
prominent marker of epithelial phenotype [195]. GSK3β has also been shown to inhibit the 
function of NFκB, which is an activator of Snail in MCF10A cells and this is the mechanism 
proposed by which GSK3β helps epithelial cells to retain the epithelial phenotype [194]. Like Snail, 
Slug is known to bind and inhibit the expression of E-cadherin. Phosphorylation of Slug by GSK3β 
marks it for ubiquitination and subsequent degradation by carboxyl terminus of Hsc70-interacting 
protein (CHIP) [196]. 
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In summary, GSK3β functions in diverse manners to facilitate the progression of cell cycle, 
promotes apoptosis and facilitates cellular migration. Thus, the effect of inhibition of GSK3β is 
dependent on the cumulative effect of GSK3β on all the different cellular processes. Inhibition of 
GSK3β might stall the cell cycle and thereby decrease the proliferation of the cells while inhibiting 
apoptosis which is essential for inhibiting tumor progression. In addition to these effects inhibition 
of GSK3β is also going to inhibit the migratory potential of the cancer cell. Thus, the effect of 
GSK3β inhibitor on a cancer depends on the cell type, the pool of GSK3β affected, the substrates 
available and the cellular processes predominantly affected. This proves that the role of GSK3β 
as a tumor promoter or suppressor is entirely context dependent. 
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Chapter 2 – Statement of objective 
 
2A. Knowledge gap 
TNBCs are highly metastatic tumors that are characterized by the presence of cells that have 
undergone EMT and are enriched for cancer stem cells. As a result, there is higher risk of 
developing chemoresistance, tumor relapse and metastasis that often prove to be fatal. The 
mainstay of treatment for TNBCs is chemotherapy as they lack targeted therapy. Only about 30% 
of the tumors respond to the chemotherapy and even these eventually tend to relapse and gain 
chemoresistance [201]. The chemotherapeutic agents mainly function by killing the rapidly 
proliferating cells in the tumors. However, TNBCs are enriched with CSCs and these cells are 
unaffected by the standard of care chemotherapeutic agents. Therefore it is imperative to develop 
novel targeted therapies to treat these aggressive cancers. The Wnt signaling pathway is one of 
the most aberrantly activated pathways in TNBCs. This pathway has also been shown to play 
pivotal role in the generation and sustenance of CSCs. GSK3β is a central player in the Wnt 
signaling cascade, capable of independently regulating stemness [202]. Our goal was therefore 
to examine the role of GSK3β in promoting EMT/CSC properties driving TNBCs & identify 
potential druggable targets. Based on our preliminary findings in CSC-enriched TNBC cells, as 
well as patient survival data analyzed from publicly available databases, we formulated the 
following hypothesis. 
 
2B. Hypothesis 
GSK3β inhibition can impede epithelial-mesenchymal-transition (EMT) and cancer stem 
cell (CSC) properties and will serve as a novel drug target for EMT/CSC-enriched triple- 
negative breast cancers (TNBCs).  
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2C. Study questions – Aims 
Aim 1 - Determine if GSK3β is upregulated in breast cancer and if this upregulation has clinical 
significance. 
Aim 2 - Investigate the relationship between GSK3β and Epithelial-Mesenchymal-Transition 
(EMT) and cancer stem cell (CSCs) properties. 
Aim 3 - Test if GSK3β inhibitors can be effectively used in vivo to target CSC-enriched breast 
cancer. 
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2D. Planned systematic investigation 
 
Aim 1 - Determine if GSK3β is upregulated in breast cancer and if this upregulation has clinical 
significance. 
Q. Is GSK3β upregulated in breast cancer? 
Approach  
?
GSK3β
expression and 
TNBC prognosis
EMT & CSC
AIM 2
?
GSK3β
inhibition
Tumor progression 
and metastatic 
properties in vivo
?
?
GSK3β
inhibitor
TNBC
EMT/CSC 
enriched 
cell lines
Figure 3 – Schematic depiction of the study
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 Publicly available datasets (Ma [203], Richardson 2 [204] and TCGA [205]) were examined to 
determine if GSK3β expression is upregulated in breast cancer tissues compared to normal 
mammary tissues. 
 
Q. Does the level of expression of GSK3β correlate with patient survival? 
Approach  
 Kaplan-Meier plots were generated using KMPlotter to identify the players of the Wnt signaling 
molecule that are associated with poor survival of TNBC and basal-like breast cancer patients 
[206]. 
 
Aim 2 - Investigate the relationship between GSK3β and Epithelial-Mesenchymal-Transition 
(EMT) and cancer stem cell (CSCs) properties in TNBC cells. 
 
Q. Can GSK3β inhibitors be used to downregulate EMT in TNBC cells? 
Approaches 
 A high throughput screen was conducted to identify small molecule inhibitors capable of 
inhibiting EMT in EMT/CSC-enriched MDA MB 231 reporter cells (Expressing EMT-
reporters). 
 Western blotting and qRT-PCR assays were employed to assess the protein and mRNA 
expression of markers of the epithelial and mesenchymal phenotype of treated cells. 
 Wound-healing assay was used to assess the effect of GSK3β inhibition on the migratory 
properties of cells with mesenchymal phenotype, which are typically characterized by the 
presence of enhanced migratory potential. 
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Q. What is the effect of GSK3β inhibitors on the CSC properties of mesenchymal-like cells? 
Approaches 
 The mammosphere forming assay (surrogate assay for stemness) was utilized to examine 
the effect of GSK3β inhibition (via small molecule inhibitor and shRNA) on the sphere-
forming ability. GSK3β knock out MEFs were also used to assess the effect of GSK3β on 
the sphere forming potential of MEFs. 
 CD44/24 surface antigen profile (an indicator of the level of stemness and differentiation) 
of the mesenchymal-like cells were examined by FACS to determine the effect of GSK3β 
on the stemness of the mammary cell lines with mesenchymal and CSC properties. 
 
Q. Do GSK3β inhibitors selectively inhibit mesenchymal-like cells as compared to their epithelial 
counterparts? 
Approaches 
 Cell lines representing normal breast cells (MCF10A), epithelial transformed cancer cells 
(MCF7) and EMT/CSC enriched cancer cells (Sum159) were treated with the GSK3β 
inhibitors and their sensitivity to the inhibitors were evaluated using the MTT assay. 
 Cell lines exhibiting epithelial phenotype and mesenchymal phenotype were treated with 
the drugs selected from the small molecule screen to identify those capable of selectively 
inhibiting cells with mesenchymal properties. 
 Cells having epithelial and mesenchymal attributes and expressing green and red 
fluorescent markers respectively, were plated in equal proportions to be co-cultured. The 
co-cultures were treated with the GSK3β inhibitors and the proportion of red and green 
cells was assessed using flow cytometry. 
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Aim 3 - Test if GSK3β inhibitor can be effectively used in vivo to target CSC-enriched breast 
cancer. 
Q. Does GSK3β inhibitor alter the tumorigenic and metastatic potential of breast cancer cells? 
Approaches 
 Immortalized and experimentally transformed human mammary cell line (HMLER-Snail) 
and a highly metastatic murine mammary (4T1) cell line were used in an orthotopic model 
to assess the effect of GSK3β inhibitor on the tumor size and metastatic potential of these 
cells.  
 Immunohistochemical analysis was performed on the tissues harvested from the animals 
to determine if the drug was effective in inhibiting GSK3β and consequently EMT, in these 
cells in vivo. 
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Chapter 3 – Experimental Approaches 
Cell lines 
Immortalized human mammary epithelial cells (HMLE), HMLE cells transduced with EMT 
transcription factor Snail (HMLE-Snail), and Twist (HMLE-Twist) and HMLE cells transformed with 
Ras and overexpressing Snail transcription factor (HMLER-Snail) were grown in HMLE media, 
made by mixing MEGM (Lonza) and DMEM/F12 50:50 (Corning) and bovine pituitary extract 
(BPE) (Lonza), insulin (Sigma), hydrocortisone (Sigma), penicillin, and streptomycin (Gibco/Life 
Technologies), were added to the media. EMT/CSC enriched basal-like cell line, Sum159 were 
cultured in Ham’s F12 media (Corning) containing additional fetal bovine serum (FBS) (Sigma), 
hydrocortisone, insulin and penicillin and streptomycin. Transformed breast cancer cell line with 
epithelial phenotype, MCF7 cells were cultured in DMEM/F12 media containing 10% FBS and 
penicillin and streptomycin. HEK293T cells were grown in DMEM (Corning) with 10% FBS and 
penicillin and streptomycin and were used for transfections. TNBC representative MDA MB 231 
reporter cells that were used for the small molecule screen were grown in DMEM media with 10% 
Tet-approved FBS and penicillin and streptomycin. Highly metastatic murine breast cancer cells, 
4T1 and mouse embryonic fibroblasts (MEF) derived from wild-type and GSK3β knockout mice 
were grown in DMEM media with 10%FBS and penicillin and streptomycin. All the cell lines were 
a generous gift from the Weinberg Lab (Whitehead Institute, MIT) and the MEFs were a gift from 
the Sarbosov lab (MD Anderson Cancer Center). 
 
Plasmids used 
shRNA to GSK3β in pGIPZ, a lentiviral vector, was purchased from the MD Anderson shRNA 
core, and was used to silence GSK3β in the three mesenchymal cell lines, HMLE-Snail, HMLE-
Twist and Sum159. pMIG, a retroviral vector, was modified to express RFP and luciferase enzyme 
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to generate pMIRL plasmid, which was then used to label HMLER-Snail and 4T1 cells which were 
used for in vivo experimentation.  
 
Transduction 
Transduction is a process by which a foreign DNA is inserted into the genomic DNA of a cell via 
a viral vector. The transduction procedure is well standardized in the lab and was performed as 
described previously in [207-209]. HEK293T cells were used to produce the viral particles. The 
HEK293T cells were plated to 20% confluence. The packaging vectors required for the 
transduction vary depending on whether a retroviral or the lentiviral vector was used. In case of 
retroviral vectors, pCMV-VSV-G and pUMVC are used as packaging vectors whereas for lentiviral 
vectors, pCMV-VSV-G and pCMV-∆R8.2dpvr are used as packaging vectors. pCMV-VSV-G has 
the gene encoding the envelope protein whereas the pUMVC produces MuLV gag and pol 
required for the packaging of retrovirus and  pCMV-∆R8.2dpvr encodes the gag and pol required 
for the packaging of the lentiviral particles [210]. The retroviral or the lentiviral vector carrying the 
gene of interest or the shRNA was mixed with the appropriate packaging vectors and added to 
DMEM (without FBS) media. The transfection reagent Fugene was added to this mixture and the 
tube was gently inverted couple times to thoroughly mix the plasmids and the transfection reagent. 
This transfection mixture was incubated at room temperature for 15 min following which the 
mixture was added to the HEK293T plates in a dropwise manner. The plate was swirled gently to 
ensure that the transfection mix was uniformly distributed and the plates were incubated at 37°C 
for 12-16 hrs in an incubator. After the incubation, the HEK293T media containing the transfection 
mix was replaced with media made by mixing the HEK293T media and the media for the target 
cell line in a 1:4 ratio. This media was harvested after 24hrs, filtered and added to the target cells. 
This media contains the viral particles produced by the transfected HEK293T. This process was 
repeated twice and then the target cells that were transduced were selected based on selection 
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markers present in the viral vector. If the viral vector had a fluorescent marker, the cells are sorted 
using a flowcytometer to select the successfully transfected cells. In case of antibiotic markers, 
the transduced cells were replated in media containing the appropriate antibiotic. These 
successfully transduced cells were used for further analysis. 
 
Drugs 
Lithium chloride (LiCl), one of the oldest known GSK3β inhibitor, was dissolved in DMSO to make 
a stock concentration of 10M. Stock of 10mM BIO (Calbiochem) was made in DMSO and TWS119 
(Cayman Chemicals) was diluted in DMSO to make a stock of 10mM and were used in varying 
working concentrations as detailed in Chapter 6 and 7. 
 
MTT assay 
The MTT assays were performed according to the instructions provided in the assay insert to 
evaluate the IC50 for each of the cell type for each of the drugs. The 96-plate format was used 
for this assay. HMLE-Snail, HMLE-Twist and Sum159 cells were trypsinized and viable cells were 
counted using trypan blue. 1000 viable cells in 100ul of media were plated in each of the wells. 
The cells were allowed to attach and the following day, the cells were treated with a range of 
concentrations for each of the drugs from 0.1uM to 100uM. The control wells were treated with 
DMSO. Following the treatment, 20ul of the MTT reagent (CellTiter 96® AQueous One Solution Cell 
Proliferation Assay from Promega) was added to each of the well and the treated cells were 
incubated at 37C. The absorbance at 490 nm was measured and was normalized to the DMSO 
treated cells. The viability of the cells treated with DMSO were arbitrarily treated as 100% and the 
viability of the cells treated with the different concentration of the drugs were calculated based on 
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this. The formula used for calculating the viability of the cells treated with the drugs is as follows 
–  
%Viability = Absorbance490 of treated cells/ Absorbance490 of DMSO treated cells * 100 
Using this data, a dose response curve was generated. The X-axis was transformed to log values 
and a non-linear regression analysis was performed using Graphpad Prism to calculate the IC50 
for all the drugs used in this study. 
 
Western blot 
Immunoblot procedure is well established in the lab and was followed as described in [208, 
211].The cells that were to be studied were plated in 10 cm dishes and the cells were treated. 
Following treatment, the cells were trypsinized and collected into 1.5 ml Eppendorf tubes. The 
cells were pelleted and the pellets were treated with 100ul of the protein extraction buffer. The 
protein extraction buffer was prepared by adding kinase inhibitor (“Complete” from Roche) and 
phosphatase inhibitor (“PhosphoStop” from Roche) to the RIPA buffer (Sigma). The cell pellets 
were incubated with the protein extraction buffer for 30 min. after which the protein extracts were 
spun down and the supernatant were transferred to a new Eppendorf tube and were stored at -
20C. The concentrations were quantified using Bradford assay from Biorad. Bovine serum 
albumin (BSA) was used to generate protein standards which were used to plot a standard curve 
from which the concentration of the proteins was estimated. 50ug of proteins were aliquoted and 
added to 6X gel loading buffer consisting of bromophenol blue, glycerol and SDS. The proteins 
were further denatured by heating the protein and gel loading buffer mixture for 10 min at 90C. 
The heat denatured proteins were spun down and were loaded on to a polyacrylamide gel.  The 
polyacrylamide gel was prepared by mixing acrylamide and bis-acrylamide, resolving or stacking 
buffer, water. Ammonium persulfate (APS) and tetramethylethylenediamine (TEMED) were 
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added to catalyze the polymerization. The gels were loaded with 50ug of proteins and the 
electrophoresis was carried out with the running buffer. After running, the segregated proteins on 
SDS-PAGE gels were transferred to nitrocellulose membranes. The membranes were blocked 
with milk and the blocked membranes were probed with different antibodies, Actin (SC-1616-R, 
Santa Cruz), GSK3β (Cell Signaling), FOXC2 (from collaborator Dr.Naoyuki Miura), Fibronectin 
(610077, BD Biosciences) and β-catenin (610153, BD Biosciences). Following incubation with the 
primary antibody, the membrane was incubated with the appropriate secondary antibody 
conjugated with horse radish peroxidase. Chemiluminescence was used to detect the expression 
of the proteins. 
 
qRT-PCR 
The RNA extraction, quantification, cDNA synthesis and qRT-PCR analysis was performed using 
the lab standardized method previously described in [212].The cells to be analyzed were 
harvested and lysed using Trizol (Life Technologies). Qiagen RNA extraction kit was used to 
extract RNA from these cells. The extracted RNA was quantified using Nanodrop 
(Thermoscientific). 1000ng of RNA was used for cDNA synthesis using cDNA synthesis kit 
(Applied Biosystems). The cDNA generated was used for qRT-PCR analysis. 96 or 348 well 
formats were used for this analysis and the Vii7 system from Applied Biosystems was used to 
perform this analysis. SyBr green (Applied Biosystems) was used as the detection agent. The CT 
(threshold cycle) values generated were used to calculate ∆CT by subtracting the CT value of the 
housekeeping or control gene from the CT value of the gene of interest for the same sample. This 
serves to normalize the CT values for each sample based on the expression of the ubiquitous 
genes such as Actin or GAPDH. ∆∆CT was computed by subtracting the ∆CT of a gene in the 
control sample from the ∆CT of the same gene in the experimental sample. ∆∆CT is used to 
assess the fold change in the expression of genes by using the formula 2^∆∆CT including GSK3β, 
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Fibronectin, Vimentin, E-cadherin and Snail. The fold changes that were calculated were graphed 
using Graphpad Prism.  
 
Mammosphere assay 
The sphere assay was performed as described in [60].Cells were harvested by trypsinization and 
counted using trypan blue to ensure that the only live cells are plated for the mammosphere assay. 
1000 cells were plated into each well of the low attachment 96 well plate in 100 ul of the 
mammosphere media. The mammosphere media is MEGM media with 1% methylcellulose 
(Sigma). EGF (10ng/ml) (Sigma-Aldrich), FGF (20ng/ml) (BD Biosciences) and heparin (4ug/ml) 
(Sigma) were added to aliquots before feeding the spheres. The spheres were allowed to grow 
for 10 days after which the spheres with diameter greater that 100um were counted. For drug 
treatment, the drug was added to the media every time the media was refreshed every 2 days. 
For the pre-treatment assay, the cells were treated with GSK3β inhibitors for 24 hrs. Following 
treatment, viable cells were counted using trypan blue and were plated for the mammosphere 
assays. The mammosphere media was refreshed for every 2 days. After 10 days, the 
mammospheres were counted. 
 
FACS analysis 
The expression of CD24/44 surface antigen was performed as previously detailed in [60].Cells to 
be used for this analysis were harvested and counted using trypan blue. 5x105 cells were used 
for this analysis. The cells to be analyzed were suspended in (fluorescence activated cell sorting) 
FACS buffer (PBS with 2% FBS). CD24 conjugated with PE (BD Biosciences) and CD44 
conjugated with APC (BD Biosciences) were incubated with the cells for 30 min. on ice. Following 
the incubation, the cells were thoroughly washed with the FACS buffer which is 1% FBS in 
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Phosphate Buffer Saline (PBS). The cells resuspended in the FACS buffer were analyzed using 
BD Accuri. Unstained cells were used as negative control. FACS uses differences in the light 
scattering ability of the cells to differentiate between different populations of the cells within a 
single pool of cells. The composition of each type of cell is different and therefore scatters the 
light projected on it in differently. Similarly, the fluorescently labeled cells scatter light depending 
on the fluorophore present on the cell. FACS was used to analyze the expression of CD24 and 
CD44 on the surface of the cells and the cell surface profile thus generated were compared 
between the treated and the untreated cells. 
 
Wound healing assay 
The parameters for the wound healing assay was established and described in [208]. Cells were 
plated on 6 well plates and on coverslips (for performing immunofluorescence studies) and 
allowed to grow to confluence. Once the cells were confluent, a scratch was made using a pipette 
tip. The loosened cells were washed away using PBS. The cells were then incubated with media 
containing either DMSO or GSK3β inhibitors. The scratch was imaged for the time 0 using the 
fluorescent microscope (Axio). The initial wound was measured and was used to determine the 
percentage of wound closed. The closing of the wound was monitored. 9 hrs. after the treatment, 
the unclosed wound was measured. The cells were treated with either DMSO or GSK3β inhibitor 
and the scratch was imaged and quantified after 9 hrs. Following this the scratches were fixed for 
immunofluorescence studies. 
 
Immunofluorescence  
The immunofluorescence studies were conducted as detailed in [208]. For immunofluorescence 
studies, the cells were plated on coverslips. The cells were fixed with 2% paraformaldehyde (USB) 
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and permeabilized with Tween20 (Fisher Bioreagents). These cells were blocked with albumin 
overnight and exposed to primary antibody of interest for 3 hrs. Following this the cells were 
washed with TBST thoroughly and then exposed to the appropriate secondary antibody which 
was labeled with a fluorophore (Alexa Fluor from Life Technologies). The nuclei of the labeled 
cells were stained with DAPI and this were then mounted and covered with a coverslip. The 
labeled cells were then imaged using Axio microscope. 
 
In vivo experiment to test the efficacy of TWS119  
The in vivo studies were carried out based on the methodology described in [60]. HMLER-Snail 
and 4T1 cells were labeled with pMIRL. Therefore, the cells were red and the red cells were sorted 
using FACS to select the cells that have been successfully transduced.  pMIRL also expressed 
the luciferase gene and were used for in vivo experiments. 10 NOD/SCID mice were used for the 
HMLER-Snail experiments. 1x106 labelled cells were injected orthotopically and the cells were 
allowed to grow until palpable tumors formed (1 week). The mice were randomized into 2 groups; 
one group was control and were treated with DMSO whereas the other group was treated with 
TWS119 (30 mg/kg) intraperitoneally. Similarly, 1x104 labeled 4T1 cells were orthotopically 
injected into 20 wild-type mice. These mice were randomized into 2 groups once the mice 
developed palpable tumors (4 days). One group was treated with DMSO and the other group was 
treated with TWS119. All the mice were imaged weekly to monitor the tumor progression. At the 
end of the experiment, the mice were sacrificed and the tumors and the lungs were isolated, fixed 
and embedded. The luminescence data were analyzed and plotted.   
 
Immunohistochemistry 
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Immunohistochemical (IHC) staining was performed on the tumor samples isolated from mice 
following the procedure described in [213]. The tumor tissues were fixed with 10% formaldehyde 
(formalin) for about 12-16 hrs after which they were stored in phosphate buffered saline (PBS) 
and subsequently paraffin embedded. The paraffin embedded sections were cut to give 5μm thin 
sections which were used for the staining procedure. Following deparaffinization and rehydration, 
antigen retrieval was performed by heating the slide containing the tissue section with citrate 
buffer (pH-6) in a microwave for 20 min. Endogenous peroxidase activity was quenched using 3% 
hydrogen peroxide and the sections were blocked at room temperature with 5% BSA and 0.3% 
Triton-X in PBS for one hour. Sections thus processed, were incubated with 1:100 dilution of 
primary antibodies, overnight at 4°C. Following the removal of the primary antibodies, the slides 
were treated with Biotinylated secondary antibodies (Vector labs) for one hour and incubated with 
Vectastain ABC reagent for 30 min. Slides were treated with DAB substrate (Vector labs) for 10 
min, dehydrated, counterstained with Hematoxyllin and were mounted and imaged. All slides were 
stained simultaneously with the controls in an automated stainer (Dako AutoStainer Plus). The 
Envision Dual Link-HRP (Dako) was used for detection and diaminobenzidine was used as 
chromogen (Dako Envision Kit). Hematoxylin (Dako) was employed as counterstaining. Finally, 
the slides were dehydrated and mounted with a cover slip and imaged. 
 
Statistical Method 
All the samples were assayed in triplicate. The in vitro experiments were repeated at least three 
independent times except for the validation studies and the experiments using the 11 drugs 
isolated from the small molecule screen which were repeated 2 times. The in vivo experiments 
included at least 5 mice per group as mention in the “experimental approaches”. All the graphs 
are represented as mean±s.e.m., and  the p values (significance) were calculated using Student’s 
unpaired two-tailed t-test.  
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Chapter 4 – Aim 1 – Determine if GSK3β is upregulated in 
breast cancer and if this upregulation has clinical 
significance. 
 
4A. GSK3β is upregulated in breast cancer. 
It is very difficult to classify a kinase as a tumor suppressor or promoter as its role depends on 
the context such as availability of substrates, localization and presence of other regulatory factors. 
We analyzed several publicly available datasets and found that in the Ma dataset [203], the 
Richardson 2 dataset [204] and the TCGA data set [205] in which there is a significant 
overexpression of GSK3β in breast cancer tissues compared to normal breast tissue [214, 215] 
(Figure 4). We observed a significant upregulation of GSK3β in the Richardson data set and this 
is of note because the Richardson data set mainly comprises of basal-like breast cancer samples. 
Therefore, the upregulation of GSK3β is more marked in this dataset as compared to the other 
datasets that consist of samples of all the different types of breast cancer.  
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Figure 4 – GSK3β is significantly upregulated in breast cancer. GSK3β is significantly
upregulated at the transcript levels in cancer tissues as compared to normal tissues in the
Ma (202), Richardson 2 (203), and TCGA (204) datasets.
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4B. Elevated expression of GSK3β correlates with worse overall survival among 
TNBC patients. 
Using KM plotter, we studied the significance of the high of GSK3β in breast cancer. KMplotter is 
an online tool that allows us to query the effect of a gene of interest on the overall survival of 
patients [216]. This tool pools all the available patient survival data from multiple databases and 
probes all the data available for the gene queried and generates a KM plot where the patients are 
classified as high or low-expressing based on the median gene expression in the dataset. KM 
plots are survival curves generated to indicate the time to an event [217]. We found that the higher 
expression of GSK3β corresponds to worse overall survival in breast cancer patients. The breast 
cancer patients were classified on the basis of the intrinsic subtype and a similar correlation 
between elevated expression of GSK3β and worse survival was observed in patients with Luminal 
A breast cancer, luminal B breast cancer and basal breast cancer (Figure 5). The hazard ratio for 
several major players in different sub-types of breast cancer were extracted and tabulated in 
Table 1 and plotted using Circos plot (Figure 6). Of all the Wnt signaling molecules examined, 
GSK3B and FZD2 had HR greater than 1 in all the 4 categories of breast cancers investigated 
indicating that higher level of expression of these genes correlate with worse overall survival in 
these patients. However, the correlation between the expression of FZD2 and the overall survival 
in the breast cancer patients examined in this section was not significant (p>0.01) (Table 1). 
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Figure 5 – Higher GSK3β expression correlates with worse overall breast cancer survival.
Kaplan Meier (Km) Plots for GSK3β in all breast cancer (A), luminal A (B), luminal B (C),
and basal-like breast cancers (D)..
A B
C D
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All Luminal A Luminal B Basal
HR P HR P HR P HR P
1 GSK3B 1.67 (1.49-1.88) 0 1.35 (1.13-1.63) 0.0011 1.78 (1.44-2.19) 0.000000038 1.93 (1.48-2.53) 0.00000094
2 FZD5 1.1 (0.98-1.23) 0.11 1.1 (0.92-1.32) 0.3038 1.03 (0.84-1.26) 0.77 0.74 (0.57-0.97) 0.027
3 FZD2 1.09 (0.97-1.22) 0.16 1.13 (0.94-1.35) 0.2 1.3 (1.06-1.6) 0.011 1.09 (0.84-1.41) 0.5363
4 FZD1 0.96 (0.86-1.08) 0.51 0.86 (0.72-1.03) 0.107 1.09 (0.89-1.34) 0.39 1.08 (0.84-1.4) 0.5487
5 LRP6 0.94 (0.84-1.06) 0.32 0.84 (0.7-1.01) 0.0632 1.12 (0.91-1.37) 0.27 0.88 (0.68-1.14) 0.3277
6 WIF1 0.92 (0.82-1.03) 0.16 0.84 (0.7-1.01) 0.0663 0.95 (0.78-1.17) 0.6399 0.72 (0.55-0.94) 0.0139
7 APC 0.89 (0.79-1) 0.046 0.8 (0.67-0.96) 0.018 0.97 (0.79-1.18) 0.75 1.22 (0.94-1.59) 0.127
8 DKK1 0.87 (0.78-0.98) 0.0182 0.73 (0.61-0.88) 0.0007 0.88 (0.72-1.08) 0.24 0.7 (0.54-0.9) 0.0062
9 CTNNB1 0.87 (0.77-0.97) 0.014 0.79 (0.66-0.94) 0.0099 0.85 (0.69-1.04) 0.1104 1.21 (0.93-1.57) 0.1564
10 FZD3 0.83 (0.74-0.93) 0.0015 0.83 (0.69-0.99) 0.041 0.84 (0.68-1.03) 0.087 0.8 (0.61-1.03) 0.0856
11 DVL1 0.81 (0.72-0.91) 0.00042 0.76 (0.64-0.92) 0.0036 0.91 (0.74-1.11) 0.3621 0.88 (0.68-1.14) 0.3406
12 FZD8 0.81 (0.72-0.91) 0.00034 0.86 (0.72-1.03) 0.11 0.75 (0.61-0.91) 0.0047 0.86 (0.66-1.11) 0.2494
13 LRP5 0.81 (0.72-0.91) 0.00038 0.71 (0.59-0.86) 0.00027 0.85 (0.69-1.04) 0.12 0.8 (0.62-1.04) 0.096
14 FZD4 0.8 (0.71-0.89) 0.00011 0.69 (0.57-0.83) 0.000061 0.91 (0.75-1.12) 0.38 0.88 (0.68-1.14) 0.34
15 AXIN1 0.76 (0.67-0.85) 2.10E-06 0.79 (0.65-0.94) 0.0089 0.71 (0.58-0.87) 0.00081 0.74 (0.57-0.96) 0.0216
16 GSK3A 0.75 (0.67-0.84) 8.10E-07 0.68 (0.57-0.82) 0.000038 0.78 (0.63-0.95) 0.015 0.74 (0.57-0.96) 0.0222
17 WNT3 0.73 (0.65-0.82) 8.80E-08 0.78 (0.65-0.94) 0.0074 0.94 (0.77-1.1) 0.58 1.12 (0.87-1.46) 0.3756
18 LEF1 0.71 (0.64-0.8) 9.10E-09 0.8 (0.67-0.96) 0.018 0.76 (0.62-0.93) 0.0073 0.73 (0.56-0.95) 0.017
19 DVL2 0.68 (0.6-0.76) 4.80E-11 0.62 (0.52-0.75) 0.0000003 0.75 (0.61-0.92) 0.0053 0.66 (0.51-0.86) 0.0018
20 TCF7 0.67 (0.59-0.75) 5.80E-12 0.75 (0.62-0.9) 0.0016 0.56 (0.46-0.69) 0.000000028 0.72 (0.55-0.93) 0.0119
Table 1 – List of the hazard ratios and p-value of the players of the Wnt signaling in breast
cancers.y.
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Additionally, KM plots were also generated for breast cancers based on the clinical classifications 
i.e. ER/PR+, HER2+ and TNBCs. The KM plots indicated that there was no significant correlation 
between the level of GSK3β expression and the overall survival of the patients with ER/PR+ or 
HER2+ breast cancers (Figure 7). In the case of ER/PR+ breast cancers the hazard ratio was 1.6 
Figure 6 – Circos plot of the hazard ratios of components of Wnt signaling pathway. The
hazard ratio (HR) from the Km Plots for all the components of the Wnt signaling pathways
were plotted using Circos. The green bar marks the upper limit of the HR, the purple bar
plots the lower limit of HR and the blue bars plot the average HR. The HRs indicate that
GSK3β has the highest HR among all the Wnt signaling pathway players in all the subtypes
of breast cancer.
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and the p-value was 0.08. In the case of HER2 + breast cancer patients, the hazard ratio was 
0.81 and the p-value was 0.6. However, in the case of TNBCs, the hazard ratio for GSK3β was 
2.22 and this value was higher than that for most of the other major players in the Wnt signaling 
pathway and with a significant p-value of 0.0051 (Figure 7). Thus the correlation between the 
overexpression of GSK3β and the worse overall survival was found to be significant only in the 
patients with TNBC (Figure 7). Among the Wnt signaling pathway players tested, GSK3β was the 
only molecule for which the correlation between the expression and survival was significant in 
TNBCs (Figure 8).  
 
Summary – Aim 1: Thus far, we examined multiple datasets to assess the level of expression of 
GSK3β in tumor tissues in comparison with that in the normal breast tissues. We found that 
GSK3β was highly upregulated in breast cancer tissues as compared to the normal breast tissues 
in Ma dataset, Richardson 2 dataset and the TCGA. This indicated that the expression of GSK3β 
is dysregulated in breast cancers.  We then analyzed publicly available patient survival data using 
KMPlotter to determine if there is a significant correlation between the expression of GSK3β and 
other Wnt signaling molecules in TNBC and indeed observed a significant correlation between 
elevated levels of GSK3β and worse overall survival among TNBC patients. Our results taken 
together serve to establish the basis for testing GSK3β as a potential target for TNBCs. 
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Figure 7 – The upregulation of GSK3β significantly correlated with worse survival of
TNBCs. Kaplan Meier Plots were generated for ER/PR+, HER2+ and TNBC patients to
determine how GSK3β correlates with the survival of these patients. The upregulation of
GSK3β significantly correlated with worse survival only in TNBCs and no significant
correlation was observed in other types of breast cancer.
ER/PR+ HER2+
TNBC
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Figure 8 – GSK3β is the only signaling molecule in the Wnt signaling pathway that has a
high hazard ratio and a significant p-value. Hazard ratios and the p-values for several of the
major players of the Wnt signaling pathway were generated and plotted for TNBC patients.
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Chapter 5 – Aim 2 – Investigate the relationship between 
GSK3β and Epithelial-Mesenchymal Transition (EMT) and 
cancer stem cells (CSCs) in TNBCs 
 
 
5A. Small molecule screen indicates that BIO is a potential candidate capable 
of decreasing mesenchymal phenotype. 
A small molecule screen was conducted using MDA MB 231 reporter cells [218] (Figure 9). The 
reporter cells have a Zeb1 reporter and E-cadherin promoter reporter. The Zeb1 reporter consists 
of the 3’ UTR of Zeb1 that is cloned downstream the gene coding for GFP. When the cells have 
a mesenchymal phenotype, miR200 expression is low and it cannot bind to the 3’ UTR of Zeb1 
and therefore the expression of GFP, which is cloned upstream the 3’UTR of Zeb1 gene, is not 
inhibited and the cells are green in color. When EMT is inhibited, the cells upregulate the 
expression of miR200 which can now bind to the 3’UTR of Zeb1 and inhibit the expression of 
Zeb1 gene and the expression of GFP in the Zeb1 reporter. Hence the green coloration 
associated with mesenchymal properties is lost. The reporter cells also have an E-cadherin 
promoter reporter in which dsRed is cloned behind the E-cadherin promoter. Therefore, with the 
acquisition of epithelial phenotype the cells express E-cadherin and as a result dsRed cloned 
downstream the E-cadherin promoter is turned on and the cells become red. The reporter cells 
also express doxycycline (dox)-inducible miR200 which was used as a positive control. 
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The MDA MB 231 reporter cells were plated in 384 wells and were treated with a library of small 
molecule inhibitors listed in Table 2-14. The cells were treated with three different concentrations 
(0.1μM, 1μM and 10μM) of each of drug in the library for 5 days, following which the plates were 
scanned for the presence of red and green fluorescence. The ratio of red to green was calculated 
for all the wells and 11 drugs that produced a ratio greater than 1.5 were selected (Table 15). The 
short listed drugs consisted of kinase inhibitors and histone deacetylase (HDAC) inhibitors. It was 
interesting to note that among all the compounds tested, BIO, a GSK3β inhibitor was one of the 
candidates that were able to decrease Zeb1 promoter activity (green) and increase E-cadherin 
promoter activity (red) in the reporter cells. 
 
 
Ubc d2GFP Zeb13’UTR
miR200
Ubc d2GFP Zeb13’UTR
Ubc
Ecad
Promoter
dsRed
Ecad Promoter dsRed
Tre rtTA3
miR200 UbcTre rtTA3 Dox
EMT Inhibitor
Figure 9 – MDA MB 231 reporter cell line. The MDA MB 231 reporter cells generated by
Toneff et. al. (217) were used to screen the drugs for their ability to inhibit EMT. When EMT
is inhibited, miR200 is expressed and suppresses the expression of Zeb1, thereby
suppressing the expression of GFP. In the meanwhile, E-Cadherin expression is turned on
and therefore the RFP is turned on. Thus the cells in which EMT is inhibited lose the green
color and gain red fluorescence.
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Drugs used in the small molecule screen 
1 FG-4592 45 Dovitinib (TKI-258, CHIR-258)
2 Panobinostat (LBH589) 46 Sunitinib Malate
3 Obatoclax Mesylate (GX15-070) 47 HA14-1
4 LAQ824 (Dacinostat) 48 U0126-EtOH
5 Varespladib (LY315920) 49 JNJ-38877605
6 Cabozantinib (XL184, BMS-907351) 50 SRT1720
7 Malotilate 51 17-AAG (Tanespimycin)
8 Barasertib (AZD1152-HQPA) 52 Capecitabine
9 PA-824 53 Cisplatin
10 JNJ-26854165 (Serdemetan) 54 Plinabulin (NPI-2358)
11 ENMD-2076 55 Raltitrexed
12 Nintedanib (BIBF 1120) 56 Ridaforolimus (Deforolimus, MK-8669)
13 Motesanib Diphosphate (AMG-706) 57 Temsirolimus (CCI-779, NSC 683864)
14 Nutlin-3 58 Belinostat (PXD101)
15 BTZ043 Racemate 59 GDC-0879
16 Foretinib (GSK1363089) 60 Odanacatib (MK-0822)
17 Everolimus (RAD001) 61 YM155 (Sepantronium Bromide)
18 Brivanib Alaninate (BMS-582664) 62 17-DMAG (Alvespimycin) HCl
19 Docetaxel 63 CEP-18770 (Delanzomib)
20 AT13387 64 CP-724714
21 WZ4002 65 Regorafenib (BAY 73-4506)
22 Danoprevir (ITMN-191) 66 CUDC-101
23 Afatinib (BIBW2992) 67 Erlotinib HCl (OSI-744)
24 NVP-AEW541 68 Trichostatin A (TSA)
25 AUY922 (NVP-AUY922) 69 NVP-ADW742
26 MLN8054 70 OSU-03012 (AR-12)
27 SGX-523 71 Palbociclib (PD-0332991) HCl
28 TW-37 72 Alisertib (MLN8237)
29 ADL5859 HCl 73 Ivacaftor (VX-770)
30 SNS-314 Mesylate 74 MK-8245
31 Lenvatinib (E7080) 75 WZ3146
32 MK-2866 (GTx-024) 76 WZ8040
33 BIBR 1532 77 TAK-700 (Orteronel)
34 BMS-536924 78 Lapatinib (GW-572016) Ditosylate
35 Sorafenib Tosylate 79 Y-27632 2HCl
36 PHA-665752 80 OSI-906 (Linsitinib)
37 Vatalanib (PTK787) 2HCl 81 Danusertib (PHA-739358)
38 GSK690693 82 XL147
39 BMS-754807 83 AT9283
40 Andarine 84 SNS-032 (BMS-387032)
41 S3I-201 85 Ganetespib (STA-9090)
42 ABT-751 (E7010) 86 CYC116
43 BIIB021 87 XAV-939
44 Aprepitant 88 Irinotecan
Table 2 – List of the drugs from the Sellekchem small molecule library that were tested in 
with their commonly used acronyms in parenthesis.
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89 Decitabine 133 Tivozanib (AV-951)
90 PFI-1 (PF-6405761) 134 Oxaliplatin
91 Amuvatinib (MP-470) 135 Enzalutamide (MDV3100)
92 Rufinamide 136 Avagacestat (BMS-708163)
93 Asenapine 137 Ki16425
94 Flupirtine maleate 138 Losartan Potassium (DuP 753)
95 Ki8751 139 Cefoselis Sulfate
96 Drospirenone 140 Meropenem
97 Pirarubicin 141 Tenofovir 
98 Bafilomycin A1(Baf-A1) 142 Sildenafil Citrate
99 Nanchangmycin 143 PHA-680632
100 Dimesna 144 Nelarabine 
101 Clofarabine 145 KU-0063794
102 Latrepirdine 146 Dienogest
103 Posaconazole 147 PD173074
104 Biperiden HCl 148 Costunolide
105 Ginkgolide B 149 GSK1059615
106 Epothilone B (EPO906, Patupilone) 150 Daptomycin
107 Ruxolitinib (INCB018424) 151 Mizoribine 
108 Rocuronium Bromide 152 Tigecycline
109 Droxinostat 153 Tianeptine sodium
110 Aurora A Inhibitor I 154 Cilomilast
111 Dutasteride 155 Bleomycin Sulfate
112 OSI-930 156 2-Methoxyestradiol (2-MeOE2)
113 Vinblastine 157 Entecavir Hydrate
114 Prasugrel 158 WYE-354
115 Budesonide 159 Dexamethasone (DHAP)
116 Granisetron HCl 160 MGCD-265
117 BMS-707035 161 Doripenem Hydrate
118 Isotretinoin 162 Nafamostat Mesylate
119 Stavudine (d4T) 163 Trilostane
120 Ranolazine 2HCl 164 Varenicline Tartrate
121 Ispinesib (SB-715992) 165 Zibotentan (ZD4054)
122 PIK-75 166 Carboplatin
123 Dexrazoxane HCl (ICRF-187, ADR-529) 167 Agomelatine
124 JNJ-7706621 168 Nepafenac
125 Cinacalcet HCl 169 Adapalene
126 Epothilone A 170 Etodolac 
127 TG100-115 171 Rigosertib (ON-01910)
128 Bafetinib (INNO-406) 172 Gestodene
129 Lopinavir 173 Pelitinib (EKB-569)
130 Tenofovir Disoproxil Fumarate 174 Bimatoprost
131 Rilmenidine 175 Elaiophylin
132 Tipifarnib 176 Atazanavir Sulfate
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177 VX-745 221 Doxercalciferol
178 GW501516 222 Oligomycin A
179 Iloperidone 223 PHA-793887
180 LY2228820 224 Pracinostat (SB939)
181 SAR245409 (XL765) 225 Vinorelbine 
182 BIX 02189 226 DMXAA (Vadimezan)
183 MK-3207 HCl 227 Dapagliflozin
184 PHT-427 228 Pomalidomide
185 BS-181 HCl 229 Tie2 kinase inhibitor
186 Erteberel (LY500307) 230 Darunavir Ethanolate
187 Erythromycin 231 Enalaprilat Dihydrate
188 Thiazovivin 232 Calcifediol
189 GSK429286A 233 VX-222 (VCH-222, Lomibuvir)
190 MC1568 234 Naratriptan 
191 Mycophenolate Mofetil 235 Natamycin 
192 AT7519 236 LY2811376
193 R406 (free base) 237 Telaprevir (VX-950)
194 AM1241 238 Nebivolol 
195 AT7867 239 PD318088
196 Fasudil (HA-1077) HCl 240 Candesartan 
197 Cefoperazone 241 Triamcinolone Acetonide
198 Amphotericin B 242 Lubiprostone 
199 AZD6482 243 TSU-68 (SU6668, Orantinib)
200 Pimasertib (AS-703026) 244 Zosuquidar (LY335979) 3HCl
201 HMN-214 245 PIK-93
202 Lactulose 246 CCT129202
203 MK-1775 247 Hesperadin
204 Org 27569 248 Saxagliptin
205 SB408124 249 Pimobendan
206 BMS-777607 250 Tazarotene 
207 BIRB 796 (Doramapimod) 251 Apixaban
208 Silodosin 252 Allopurinol 
209 Amprenavir 253 Amorolfine HCl
210 Marbofloxacin 254 Safinamide Mesylate
211 SB525334 255 Daclatasvir (BMS-790052)
212 AEE788 (NVP-AEE788) 256 Ponatinib (AP24534)
213 Cyclosporine 257 Tosedostat (CHR2797)
214 Quizartinib (AC220) 258 BIX 02188
215 CP-673451 259 EX 527 (Selisistat)
216 Febuxostat 260 AZD8055
217 VX-809 (Lumacaftor) 261 KU-60019
218 RO4929097 262 Semagacestat (LY450139)
219 Prilocaine 263 Allopurinol Sodium 
220 Telbivudine 264 Flurbiprofen
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265 Ipratropium Bromide 309 Desonide
266 Adefovir Dipivoxil 310 Esomeprazole Magnesium
267 Quetiapine Fumarate 311 Verteporfin 
268 Fenoprofen Calcium 312 Azithromycin
269 Potassium Iodide 313 Alibendol
270 Nefiracetam 314 Elvitegravir (GS-9137, JTK-303)
271 PCI-34051 315 Benidipine HCl
272 Epalrestat 316 Lornoxicam
273 Tiopronin 317 Mecarbinate
274 Cilazapril Monohydrate 318 Fenoldopam
275 Isepamicin 319 Temocapril
276 Betamethasone Dipropionate 320 Divalproex Sodium
277 Azathioprine 321 Gadodiamide 
278 Cefditoren Pivoxil 322 Teniposide 
279 Erdosteine 323 Albendazole Oxide
280 Talc 324 Irsogladine
281 Cyclocytidine HCl 325 Maraviroc
282 PF-573228 326 Ginkgolide A
283 Phentolamine Mesylate 327 Cytidine
284 Pamidronate 328 Atorvastatin Calcium 
285 Trimebutine 329 Dexmedetomidine HCl 
286 Almotriptan Malate 330 Rasagiline Mesylate
287 Meprednisone 331 Emtricitabine 
288 Terbinafine 332 Oxybutynin 
289 Chlorprothixene 333 Ranitidine
290 Pranlukast 334 Flubendazole
291 Vitamin B12 335 Nystatin (Fungicidin)
292 Methscopolamine 336 Raltegravir (MK-0518)
293 BMS-265246 337 Uridine
294 Cyproterone Acetate 338 Gimeracil
295 Balofloxacin 339 Moexipril HCl
296 Ivabradine HCl 340 Betaxolol
297 Ambrisentan 341 Naltrexone HCl
298 Betamethasone Valerate 342 Deferasirox 
299 Rifabutin 343 Pitavastatin Calcium 
300 Oxytetracycline (Terramycin) 344 Acadesine
301 Atracurium Besylate 345 Dapoxetine HCl 
302 Fluvastatin Sodium 346 Rimantadine 
303 Adenine HCl 347 Pramipexole 2HCl Monohydrate 
304 Suplatast Tosylate 348 Fenticonazole Nitrate
305 Doxifluridine 349 Terazosin HCl 
306 Lafutidine 350 Clevidipine Butyrate
307 Rivastigmine Tartrate 351 Detomidine HCl
308 Temocapril HCl 352 Imidapril HCl
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353 Cisatracurium Besylate 397 Licofelone
354 Atropine 398 Neratinib (HKI-272)
355 Dabigatran Etexilate 399 Tebipenem Pivoxil
356 Bazedoxifene Acetate 400 AG-14361
357 SB743921 401 Avasimibe
358 CYT997 (Lexibulin) 402 Raf265 derivative
359 PIK-293 403 Mubritinib (TAK 165)
360 Apatinib 404 CAL-101 (Idelalisib, GS-1101)
361 LY2157299 405 Palomid 529 (P529)
362 AR-42 406 (+)-Usniacin
363 Andrographolide 407 Bergenin
364 Dronedarone HCl 408 Dextrose
365 Roflumilast 409 LDE225 (NVP-LDE225,Erismodegib)
366 LY2608204 410 RAF265 (CHIR-265)
367 PD128907 HCl 411 LY2784544
368 BGJ398 (NVP-BGJ398) 412 AZD8931 (Sapitinib)
369 A-966492 413 BMS-794833
370 Vinflunine Tartrate 414 PP242
371 PF-3716556 415 PIK-294
372 Telatinib 416 Fesoterodine Fumarate 
373 Abiraterone Acetate 417 3-Indolebutyric acid (IBA)
374 Asiatic Acid 418 Bilobalide
375 Conivaptan HCl 419 S- (+)-Rolipram
376 AZD8330 420 Sitafloxacin Hydrate
377 LY2886721 421 AZD1480
378 Rosuvastatin Calcium 422 MLN2238
379 AST-1306 423 GSK461364
380 SGI-1776 free base 424 NVP-BHG712
381 AZ 960 425 CYT387
382 UK 383367 426 VX-765
383 Esomeprazole Sodium 427 GW791343 HCl
384 BKM120 (NVP-BKM120, Buparlisib) 428 Aloe-emodin
385 Azomycin 429 Cinchonidine
386 Arbidol HCl 430 Bazedoxifene HCl
387 GSK1292263 431 CGS 21680 HCl
388 KW-2449 432 PF-4708671
389 Givinostat (ITF2357) 433 MLN9708
390 SB505124 434 R406
391 Aliskiren Hemifumarate 435 OSI-420
392 DAPT (GSI-IX) 436 SB590885
393 TAME 437 Eltrombopag
394 Volasertib (BI 6727) 438 Degrasyn (WP1130)
395 CX-4945 (Silmitasertib) 439 Laetrile
396 Baicalin 440 Cyclosporin A 
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441 Dihydroartemisinin (DHA) 485 Gramine
442 Kaempferol 486 Methyl-Hesperidin
443 Naringin 487 Oridonin
444 Puerarin 488 Sclareol
445 Stigmasterol 489 Ursolic Acid
446 Ammonium Glycyrrhizinate 490 Evodiamine
447 Indirubin 491 Rheochrysidin
448 Sophocarpine 492 Paeoniflorin
449 Astragaloside A 493 Rotundine
450 Levosimendan 494 Hexestrol
451 Manidipine 2HCl 495 Quinine HCl Dihydrate
452 Enoxolone 496 Gynostemma Extract
453 L-(+)-Rhamnose Monohydrate 497 Morin Hydrate
454 Neohesperidin Dihydrochalcone (Nhdc) 498 Orotic acid (6-Carboxyuracil)
455 Quercetin Dihydrate 499 Sclareolide
456 Tanshinone I 500 Vanillylacetone
457 Biochanin A 501 Gastrodin
458 Lappaconite HBr 502 Salidroside
459 Curcumol 503 Geniposide
460 20-Hydroxyecdysone 504 Synephrine HCl
461 Forskolin 505 Itraconazole
462 Ozagrel 506 Roxithromycin 
463 Ergosterol 507 Hyodeoxycholic acid (HDCA)
464 Magnolol 508 Myricetin
465 Neohesperidin 509 Oxymatrine
466 Rutaecarpine 510 Shikimic Acid
467 Tetrahydropapaverine HCl 511 5-hydroxytryptophan (5-HTP)
468 Dioscin 512 Hematoxylin
469 Naringin Dihydrochalcone 513 Dihydromyricetin
470 Cephalomannine 514 Genipin
471 Aloperine 515 Guanosine
472 Equol 516 Lincomycin HCl 
473 D-Pantothenic acid 517 Scopolamine HBr
474 Glycyrrhizic Acid 518 Icariin
475 (+)-Matrine 519 Myricitrin
476 Oleanolic Acid 520 (-)-Parthenolide
477 Salinomycin 521 Silymarin
478 Troxerutin 522 Aloin
479 D-Mannitol 523 Hordenine
480 Sesamin 524 Sodium Danshensu
481 10-Deacetylbaccatin-III 525 Geniposidic acid
482 Apocynin 526 Inosine
483 Clindamycin HCl 527 Manidipine
484 Propafenone HCl 528 Vardenafil HCl Trihydrate
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529 Xylazine HCl 573 Ciclopirox 
530 Ceftiofur HCl 574 Trospium chloride 
531 Hydralazine HCl 575 Prednisolone Acetate 
532 Pramiracetam 576 Lonidamine
533 MG-132 577 OSI-027
534 PF-05212384 (PKI-587) 578 BMS-378806 
535 A66 579 PF-04929113 (SNX-5422)
536 WYE-125132 (WYE-132) 580 PF-3845
537 Trametinib (GSK1120212) 581 Ibrutinib (PCI-32765)
538 PF-2545920 582 BMY 7378
539 Nepicastat (SYN-117) HCl 583 KX2-391
540 Epinephrine Bitartrate 584 L-Ascorbyl 6-palmitate
541 Scopine 585 Tolterodine tartrate
542 Cloxacillin Sodium 586 Streptomycin sulfate
543 Clindamycin palmitate HCl 587 Ribitol
544 GSK256066 588 Fostamatinib (R788)
545 PNU-120596 589 NPS-2143
546 TAK-875 590 GSK2126458 (GSK458)
547 ICG-001 591 Dolutegravir (GSK1349572)
548 A922500 592 CHIR-124
549 R547 593 TG101209
550 GDC-0980 (RG7422) 594 GSK1838705A
551 L-Adrenaline 595 Ritodrine HCl 
552 Tiotropium Bromide hydrate 596 Sulbactam sodium 
553 Amoxicillin Sodium 597 Dimethyl Fumarate
554 Oseltamivir phosphate 598 Noradrenaline bitartrate monohydrate
555 AZD5438 599 LY2603618
556 GW3965 HCl 600 DCC-2036 (Rebastinib)
557 NU7441 (KU-57788) 601 5-hydroxymethyl Tolterodine (PNU 200577, 5-HMT, 5-HM)
558 WAY-100635 Maleate 602 A-674563
559 BRL-15572 603 KW-2478
560 WAY-600 604 Resminostat
561 RS-127445 605 LY2109761
562 Phenytoin sodium 606 Isoconazole nitrate 
563 Scopine HCl 607 Cortisone acetate 
564 Medroxyprogesterone acetate 608 Tolvaptan
565 Tioxolone 609 TAK-733
566 Omecamtiv mecarbil (CK-1827452) 610 Tubastatin A HCl
567 URB597 611 CCT128930
568 SNX-2112 (PF-04928473) 612 MK-0752
569 Clinofibrate 613 PF-00562271
570 Flavopiridol HCl 614 NVP-BSK805 2HCl
571 ADX-47273 615 XL335
572 CH5132799 616 YO-01027
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617 Geldanamycin 661 AMG-900
618 Dacomitinib (PF299804, PF299) 662 MK-8776 (SCH 900776)
619 MK-4827 (Niraparib) 663 AMG-458
620 Milciclib (PHA-848125) 664 TH-302
621 Alectinib (CH5424802) 665 Dovitinib (TKI-258) Dilactic Acid  
622 MK-2461 666 GW842166X
623 AZD2014 667 INCB28060
624 Torcetrapib 668 HCV-796 (Nesbuvir)
625 CEP-33779 669 INK 128 (MLN0128)
626 Torin 2 670 OC000459
627 Torin 1 671 SAR131675
628 LY411575 672 ZM 336372
629 SB415286 673 TG101348 (SAR302503)
630 PF-04691502 674 Anacetrapib (MK-0859)
631 HER2-Inhibitor-1 675 CUDC-907
632 MK-2048 676 MK-5108 (VX-689)
633 Nocodazole 677 M344
634 TAK-285 678 Tofacitinib (CP-690550,Tasocitinib)
635 VU 0357121 679 AZD4547
636 Dabrafenib (GSK2118436) 680 Ciproxifan
637 CI994 (Tacedinaline) 681 Tideglusib
638 Clindamycin 682 BI-D1870
639 CP-91149 683 JTC-801
640 Crenolanib (CP-868596) 684 PAC-1
641 CCT137690 685 BGT226 (NVP-BGT226)
642 Tivantinib (ARQ 197) 686 Canagliflozin
643 3-Methyladenine 687 Dalcetrapib (JTT-705, RO4607381)
644 CPI-613 688 I-BET151 (GSK1210151A)
645 A-803467 689 Istradefylline
646 WP1066 690 Galeterone
647 GDC-0068 691 BYL719
648 TAE226 (NVP-TAE226) 692 ML133 HCl
649 ARN-509 693 Cathepsin Inhibitor 1
650 TAK-901 694 PH-797804
651 AZ 3146 695 GSK1070916
652 AZ 628 696 GW788388
653 Varlitinib 697 NVP-BVU972
654 Dinaciclib (SCH727965) 698 SB705498
655 PF-5274857 699 GW4064
656 Laquinimod 700 Sotrastaurin
657 Lonafarnib 701 Sirtinol
658 MPEP 702 Tyrphostin AG 879
659 RG108 703 Desmethyl Erlotinib (CP-473420, OSI-774)
660 R428 (BGB324) 704 SB269970 HCl
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705 BRL-54443 749 MK-801 (Dizocilpine)
706 CTEP (RO4956371) 750 U-104
707 GW5074 751 A-205804
708 VU 0361737 752 MLN0905
709 Lumiracoxib 753 Pirfenidone
710 GW9662 754 Mozavaptan
711 CHIR-99021 (CT99021) HCl 755 Pifithrin-α (PFTα)
712 Rivaroxaban 756 Deuterated Atazanivir-D3-2
713 Piceatannol 757 Vildagliptin (LAF-237)
714 Purmorphamine 758 Solifenacin succinate
715 Azilsartan Medoxomil 759 Diclofenac Diethylamine
716 BML-190 760 StemRegenin 1 (SR1)
717 VU 0364770 761 Alogliptin
718 Camostat Mesilate 762 PJ34
719 SB742457 763 Cobicistat (GS-9350)
720 PF-477736 764 Tempol
721 ML161 765 PF-4981517
722 Evacetrapib (LY2484595) 766 Pifithrin-μ
723 Telithromycin 767 Deuterated Atazanivir-D3-3
724 Fenoprofen calcium hydrate 768 Sitaxentan sodium
725 Cinepazide maleate 769 Bosentan Hydrate
726 Medetomidine HCl 770 Guanosine Hydrate
727 MRS 2578 771 Golvatinib (E7050)
728 ML130 (Nodinitib-1) 772 TG100713
729 Prucalopride 773 PF-562271
730 ZM 323881 HCl 774 CCG 50014
731 JNJ-7777120 775 WZ811
732 HC-030031 776 Icotinib
733 Apoptosis Activator 2 777 Carbazochrome sodium sulfonate (AC-17)
734 Zanamivir 778 Rimonabant
735 Linagliptin 779 Bepotastine Besilate
736 Azilsartan 780 Rupatadine Fumarate
737 Epinephrine HCl 781 Vanillin 
738 SB271046 782 IEM 1754 dihydrobroMide
739 VUF 10166 783 T0070907
740 Acesulfame Potassium 784 GW441756
741 ZM 306416 785 S-Ruxolitinib (INCB018424)
742 Ki16198 786 Dapivirine (TMC120)
743 IOX2 787 Salubrinal
744 TAK-715 788 Clevudine 
745 Zaltoprofen 789 PMSF 
746 Bindarit 790 Fosaprepitant dimeglumine salt
747 Otilonium Bromide 791 Azelnidipine
748 Diclofenac Potassium 792 Caspofungin Acetate
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793 Dexmedetomidine 837 2-Thiouracil
794 Tylosin tartrate 838 Adrenalone HCl
795 Reboxetine mesylate 839 Sitagliptin phosphate monohydrate
796 Cyclamic  acid 840 Avanafil
797 Aclidinium Bromide 841 Methazolamide
798 Valganciclovir HCl 842 Vitamin D3 
799 Zinc Pyrithione 843 Vitamin A Acetate
800 Halobetasol Propionate 844 Voglibose
801 Lorcaserin HCl 845 Desvenlafaxine
802 Succinylcholine Chloride Dihydrate 846 Levodropropizine
803 Cyclizine 2HCl 847 Penfluridol
804 Etravirine (TMC125) 848 Moguisteine
805 Altrenogest 849 Azatadine dimaleate
806 Schisandrin B (Sch B) 850 Pentamidine
807 Ouabain 851 Sodium Picosulfate
808 Sennoside A 852 Olsalazine Sodium
809 Retapamulin 853 Escitalopram Oxalate
810 Ticagrelor 854 Lomerizine HCl
811 Ifenprodil Tartrate 855 Eprosartan Mesylate
812 Estradiol Benzoate 856 Triclabendazole
813 Tilmicosin 857 Deoxyarbutin
814 Bacitracin 858 Doxycycline Hyclate
815 Ulipristal 859 Sodium salicylate
816 Anagrelide HCl 860 Ticarcillin sodium
817 Betulinic acid 861 Mirabegron
818 Allylthiourea 862 Tolcapone
819 Vitamin D2 863 Nafcillin Sodium
820 Methyclothiazide 864 Guanidine HCl
821 Sulfacetamide Sodium 865 Levobetaxolol HCl
822 Difluprednate 866 Diminazene Aceturate
823 Dicloxacillin Sodium 867 Isovaleramide
824 Sodium Phenylbutyrate 868 Clorprenaline HCL
825 Azithromycin Dihydrate 869 Cyromazine
826 Indacaterol Maleate 870 Sertaconazole nitrate
827 Eletriptan HBr 871 Azlocillin sodium salt
828 Cabozantinib malate (XL184) 872 Hyoscyamine
829 Sennoside B 873 Homatropine Methylbromide
830 Doxapram HCl 874 Estradiol Cypionate
831 Sodium Nitroprusside 875 Sodium Nitrite
832 Spiramycin 876 Oxymetholone
833 Dexlansoprazole 877 Closantel Sodium
834 Desvenlafaxine Succinate 878 Pefloxacin Mesylate Dihydrate
835 Retinyl (Vitamin A) Palmitate 879 Eprazinone 2HCl
836 Amfenac Sodium Monohydrate 880 Teriflunomide
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881 1-Hexadecanol 925 Penciclovir
882 Ethacridine lactate monohydrate 926 Dirithromycin
883 Erythritol 927 Sodium ascorbate
884 Luliconazole 928 Ebastine
885 Brimonidine Tartrate 929 Bromocriptine Mesylate
886 Colistimethate Sodium 930 R-(-)-Apomorphine HCl Hemihydrate
887 Noscapine HCl 931 Mepenzolate Bromide 
888 Fosfomycin Tromethamine 932 Lithium Citrate
889 Picrotoxinin 933 Misoprostol
890 SC-514 934 Delphinidin Chloride
891 Tofacitinib (CP-690550) Citrate 935 Ataluren (PTC124)
892 Trometamol 936 Domiphen Bromide
893 Aminothiazole 937 Ribostamycin Sulfate
894 Fidaxomicin 938 Prucalopride Succinat
895 Vilazodone HCl 939 Efaproxiral Sodium
896 Benfotiamine 940 Calcium Gluceptate 
897 Emetine 941 Ractopamine HCl
898 Pinacidil 942 Nomifensine Maleate
899 Bentiromide 943 Oxeladin Citrate
900 Procodazole 944 TTNPB (Arotinoid Acid)
901 SN-38 945 Cyanidin Chloride
902 Pimecrolimus 946 AP26113
903 Climbazole 947 Cyclandelate
904 Isosorbide 948 Valnemulin HCl
905 Bucladesine Sodium Salt 949 Bromfenac Sodium
906 Tamibarotene 950 Etofibrate
907 Anisotropine Methylbromide 951 Ceftazidime Pentahydrate
908 Mepiroxol 952 Thiostrepton
909 Carbenoxolone Sodium 953 Pyrilamine Maleate 
910 Brucine 954 Oxiglutatione Disodium Salt
911 Nitarsone 955 JNK-IN-8
912 Quercetin 4'-glucoside 956 Petunidin Chloride
913 LY404039 957 PF-04880594
914 Mezlocillin Sodium 958 Cinchophen
915 Tenatoprazole 959 Liothyronine Sodium
916 Deoxycorticosterone acetate 960 Epinastine HCl
917 EUK 134 961 Nicaraven
918 Apomorphine HCl 962 Clinafoxacin HCl
919 Moxalactam Disodium 963 Tolmetin Sodium
920 Nicotine Ditartrate 964 Bekanamycin 
921 Dichlorisone Acetate 965 Pasiniazid
922 Sodium 4-aminohippurate Hydrate 966 JZL184
923 Quercetin 3,4'-di-O-β-glucopyanoside 967 Peonidin Chloride
924 NXY-059 968 EPZ005687
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969 MEK162 (ARRY-162, ARRY-438162) 1013 Birinapant
970 Stattic 1014 XL388
971 PD168393 1015 Oprozomib (ONX 0912)
972 LY2090314 1016 T0901317
973 IWP-2 1017 SANT-1
974 SCH772984 1018 (+)-JQ1
975 AMG-517 1019 XL888
976 PYR-41 1020 BMS-833923
977 AZD1080 1021 Ilomastat (GM6001, Galardin)
978 UNC1999 1022 ONX-0914 (PR-957)
979 AGI-5198 1023 GZD824
980 PP2 1024 CZC24832
981 IPI-145 (INK1197) 1025 XL019
982 AZD3514 1026 VX-661
983 FMK 1027 Cilengitide
984 IWR-1-endo 1028 KY02111
985 GDC-0032 1029 NLG919
986 AZD3839 1030 SC144
987 P22077 1031 CFTRinh-172
988 VER 155008 1032 LY2835219
989 SSR128129E 1033 AVL-292
990 I-BET-762 1034 RKI-1447
991 GDC-0152 1035 GDC-0834
992 AZD2461 1036 Wnt-C59 (C59)
993 BAY 1000394 1037 PP1
994 EMD 1214063 1038 SGC 0946
995 GSK2334470 1039 PD123319
996 BAM7 1040 Zebularine
997 3-Deazaneplanocin A (DZNeP) 1041 KPT-185
998 IU1 1042 TCID
999 Batimastat (BB-94) 1043 OTSSP167
1000 LY900009 1044 PF-543
1001 GSK2190915 (AM803) 1045 (Z)-Pugnac
1002 SGI-110 1046 Z-VAD-FMK
1003 EPZ004777 HCl 1047 Epoxomicin
1004 BMN 673 1048 EPZ5676
1005 GSK J4 HCl 1049 LDK378
1006 GSK923295 1050 (-)-Blebbistatin
1007 AZD3463 1051 NU6027
1008 MLN2480 1052 EPZ-6438
1009 LDN-57444 1053 BMS-911543
1010 Marimastat 1054 Mdivi-1
1011 LY3039478 1055 BAF312 (Siponimod)
1012 PF-04620110 1056 GlcNAcstatin
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1057 BIO 1101 AZD2858
1058 Bromosporine 1102 CO-1686 (AVL-301)
1059 SGI-1027 1103 AZ191
1060 Rilpivirine 1104 RGD (Arg-Gly-Asp) Peptides
1061 Rocilinostat (ACY-1215) 1105 Vortioxetine (Lu AA21004) HBr
1062 CEP-32496 1106 UPF 1069
1063 PRT062607 (P505-15, BIIB057) HCl 1107 Macitentan
1064 Dynasore 1108 Gefitinib (ZD1839)
1065 NSC 405020 1109 RG2833 (RGFP109)
1066 UNC1215 1110 OAC1
1067 Nexturastat A 1111 AZD1981
1068 DBeQ 1112 TAK-632
1069 Erastin 1113 JSH-23
1070 Suvorexant (MK-4305) 1114 AG-18
1071 EHop-016 1115 Empagliflozin (BI 10773)
1072 GSK2636771 1116 GDC-0349
1073 TAK-438 1117 Lomeguatrib
1074 Apremilast (CC-10004) 1118 Vorinostat (SAHA, MK0683)
1075 ABT-199 (GDC-0199) 1119 OTX015
1076 PluriSIn #1 (NSC 14613) 1120 RepSox
1077 C646 1121 MM-102
1078 ZM 39923 HCl 1122 ZCL278
1079 CNX-2006 1123 EPZ004777
1080 Ferrostatin-1 (Fer-1) 1124 PRX-08066 Maleic acid
1081 Edoxaban 1125 Tariquidar
1082 Tasisulam 1126 Scriptaid 
1083 BIX 01294 1127 Pacritinib (SB1518)
1084 AZD5363 1128 AG-490 (Tyrphostin B42)
1085 VU 0364439 1129 UNC669
1086 Tubastatin A 1130 RGFP966
1087 Bardoxolone Methyl 1131 Golgicide A
1088 OG-L002 1132 RVX-208
1089 SMI-4a 1133 Tenovin-1
1090 Thiamet G 1134 GW9508
1091 KPT-276 1135 NSC 23766
1092 JIB-04 1136 BMS-345541
1093 IOWH032 1137 P276-00
1094 VE-821 1138 WHI-P154
1095 GW0742 1139 ME0328
1096 Butein
1097 ETP-46464
1098 Dasatinib
1099 SGC-CBP30
1100 Skepinone-L
Table 2 – List of the drugs from the Sellekchem small molecule library that were tested in 
with their commonly used acronyms in parenthesis.
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All the 11 drugs that were shortlisted in the screen were validated using flow cytometry (Table 
15). The reporter cells were plated in 24-well plates. The reporter cells were treated with 3 different 
concentrations of the drugs (0.1μM, 1μM and 10μM) for 5 days and following treatment the cells 
were analyzed using flow cytometry. MDA MB 231 cells that did not express the reporters were 
used to set the quartiles to define the red positivity and green positivity. All the treated cells were 
sorted and the percentage of cells in each quartile was plotted (Figure 10). The cells that fall in 
the first quartile denote the reporter cells that have gained red color but lost the green color 
indicating that the expression of Zeb1 is turned off and the expression of E-cadherin is turned on. 
These cells are denoted in blue in Figure 10. The cells that fall in the second quartile are the cells 
that have both red and green fluorescence indicating that both Zeb1 and E-cadherin are turned 
on. Red is used to represent these cells in Figure 10. The cells that fall in the third quartile are 
cells that express green but not red fluorescence indicating that these cells have retained 
mesenchymal properties following the treatment and therefore the expression of Zeb1 is not 
Drug Target
1 TSU-68 (Orantinib) VEGFR, PDGFR, FGFR
2 Rocilinostat (ACY-1215) HDAC
3 Trichostatin A (TSA) HDAC
4 CUDC-101 HDAC, HER2, EGFR
5 PD168393 EGFR
6 SCH79797 Par1 antagonist
7 CP-673451 PDGFR
8 Panobinostat (LBH589) HDAC
9 BIO GSK3
10 Cabozantinib malate VEGFR, Axl
11 GW9662 PPAR
Table 3 – List of the drugs that were most effective in inhibiting EMT in the mesenchymal 
MDA MB 231 reporter cells and their reported targets.
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inhibited and the E-cadherin is not expressed. These cells are marked in green in the graphs in 
Figure 10. The cells that fall in the fourth quartile lack the expression of both red and green 
fluorescence and are cells that neither express Zeb1 nor E-cadherin. These cells are represented 
in purple in Figure 10. The drugs that were able to increase the expression of E-cadherin and 
consequently increase the proportion of the cells in the second quartile were selected. Among all 
the drugs tested, GSK3β inhibitor, BIO and CUDC-101 were the only drugs that effectively 
enabled the transition of the mesenchymal-like cells to red expressing reporter cells (Figure 10). 
CUDC-101 is a multi-therapeutic drug that is capable of inhibiting HER2, EGFR and HDAC [219]. 
However, we were seeking to identify novel targets for treating TNBCs that lack the amplification 
and overexpression of HER2. There are several studies examining the effect of HDAC inhibitors 
on TNBCs [220-224]. Therefore, CUDC-101 did not appear to be a good candidate for this study. 
As patient studies indicated that GSK3β could be a viable target to treat TNBCs that have been 
observed to upregulate this kinase, BIO was selected for further studies.   
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Figure 10 – CUDC1 and BIO are capable of inhibiting EMT. A. MDA MB 231 reporter cells
were treated with different doses of the drugs shortlisted from the screen for 5 days. These
cells were then analyzed using flowcytometry. Few of the drugs killed the cells and therefore
could not be analyzed. Among these drugs, only CUDC1 and BIO were capable of
decreasing the number of green positive cells while also upregulating the expression of
RFP. B. Heatmap of the ratio between red and green cells. Red indicated more epithelial
cells.
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BIO refers to 6-Bromoindirubin-3’-oxime which is a bromo derivative of indirubin [225]. Bis-indole 
alkaloid indirubin and its analogs, collectively known as indirubins, were first discovered as 
inhibitors of cyclin dependent kinases (CDKs) [225, 226]. Indigo and indirubin are isomers that 
are derived from isatin and indoxyl via non-enzymatic dimerization [225]. The 2 components of 
the indirubins are usually found free or conjugated with carbohydrates [225]. Indirubins can be 
extracted from dye- producing plants, Muricidae mollusks and wild-type and recombinant bacteria 
[226]. Interestingly, indirubin is an active ingredient in Danggui Longhui, a traditional Chinese 
medicine recipe used to treat chronic myelocytic leukemia [225]. While it was discovered as a 
CDK inhibitor, it was later determined that it could also inhibit GSK3β [225].  Recent studies have 
indicated that chemical modifications to indirubins alter their affinity for kinases and thus 6-
Bromoindirubin-3’-oxime was found to have higher affinity for GSK3β as compared to other 
kinases and methyl-derivative of BIO was found to be ineffective in binding to GSK3β [225]. 
Thus, this screen served to further attest that GSK3β may be an important player in TNBC and 
that GSK3β inhibitors could serve as a potent therapeutic agent to revert EMT/CSC properties of 
TNBC cells. 
 
5B. GSK3β inhibitors decrease the mesenchymal properties of the stem cell-
enriched mesenchymal-like cell lines. 
The small molecule screen and the subsequent validation clearly demonstrated that the GSK3β 
inhibitor, BIO is a potent inhibitor of EMT in TNBC cells. However, it was essential to test if this 
phenomenon was limited to BIO or whether this is true for other GSK3β inhibitors too. To ensure 
that our observations are robust we test 3 different GSK3β inhibitors that function via different 
mechanisms on 3 different cell lines with mesenchymal properties. The 3 GSK3β inhibitors used 
in this study include BIO, which was one of the lead candidates of the screen, LiCl, which has 
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been in the clinic for treatment of neurological disorders for more than half a decade and TWS119, 
a GSK3β inhibitor for which GSK3β is the only established target [202, 227].  
 
After 50 years of using lithium for treating manic-depression (Bipolar disorder), GSK3β was 
identified as one of its targets [227]. Lithium inhibits GSK3β via 2 different mechanisms [227]. It 
competes with the magnesium ions for binding to the kinase [227]. Magnesium ions are essential 
for the catalytic activity of kinases. The other mechanism of action of lithium is to increase the 
inhibitory serine-9 (inactivating) phosphorylation of GSK3β [227-229]. This indirect effect has 
been attributed to the effect of lithium on protein-phosphatase-1 or on the activated Akt [227, 230, 
231].  Unlike most of the other GSK3β inhibitors, lithium does not inhibit CDKs [232]. Inhibition of 
GSK3β using lithium chloride decreases the active form of GSK3β in all the 3 sub-cellular 
compartments (cytoplasm, nucleus and mitochondria) in which GSK3β has been detected and 
reported. As lithium has been in the clinic for a very long time, it has a known safety profile. 
Notably, studies have shown that prolonged use of lithium doesn’t increase tumor incidence [233, 
234].  
 
TWS119 is a 4,6-disubstituted pyrrolopyrimidine. It was originally discovered in a screen used to 
identify small molecules that were capable of inducing differentiation in P19 embryonic stem cells 
(ESC) [202]. TWS119, which was identified in this screen was shown to bind to GSK3β via affinity 
chromatography and this interaction was confirmed by western blotting and surface plasmon 
resonance (SPR) [202]. Additionally, some of the studies mentioned TWS119 to be specific for 
GSK3β inhibition [215].  
 
78 
 
The 3 cell lines consistently used in these studies include HMLE-Snail cells, HMLE-Twist cells 
and Sum159 cells. HMLE cells are human mammary epithelial cells that have been immortalized 
and have an epithelial phenotype. The overexpression of EMT inducing transcription factors Snail 
and Twist in the HMLE cells gives rise to the HMLE-Snail and HMLE-Twist cells respectively. 
Therefore, HMLE-Snail and HMLE-Twist cells are epithelial cells that have been forced to undergo 
EMT by the overexpression of EMT inducing transcription factors and thereby exhibit 
mesenchymal properties and are enriched for stem-like cells. Sum159 cells are mesenchymal-
like cells that are enriched for CSCs. All the three cell lines were treated with BIO (1uM), LiCl 
(20mM) and TWS119 (2uM) for 24hrs. These concentrations are close to IC25 calculated for 
24hrs for these drugs for the cell lines used in this experiment. The lowest IC25 among the IC25s 
of the 3 cell lines (HMLE-Snail, HMLE-Twist and Sum159) was finalized as the concentration for 
treating all the cells).  0.5x10^6 cells were plated in a 10 cm dish and the cells were allowed to 
attach overnight. The attached cells were treated with the appropriate concentration of the drugs 
and the control cells were treated with DMSO (0.05%) for 24 hrs following which the cells were 
harvested for protein and RNA extraction. The protein extraction was performed as described in 
the “Experimental approaches” section and the proteins were quantified using the BioRad 
Bradford Assay. 50ug of each protein sample was loaded onto the gel and the western blot 
analysis was performed as described in Experimental approaches. The membrane was probed 
for β-Catenin, FOXC2, Fibronectin and β-Actin. The β-Catenin levels were seen to increase 
following treatment with GSK3β inhibitors, indicating that GSK3β is indeed inhibited leading to the 
accumulation of β-Catenin in the treated cells. The expression of FOXC2 and fibronectin which 
serve as indicators of mesenchymal phenotype was decreased (Figure 11). 
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The RNA was extracted using the Qiagen RNA extraction kit and the RNA was quantified using 
the Nanodrop from Thermoscientific. The cDNA generated using this RNA was used for qRT-
PCR and the levels of expression of mesenchymal and epithelial markers fibronectin, vimentin 
and E-cadherin were tested for HMLE-Snail and HMLE-Twist cells and fibronectin, Snail and E-
cadherin were tested for Sum159 cells. The expression of the housekeeping gene, GAPDH gene 
was used for normalization. In line with the western blot analysis, we found a decrease in 
expression of mesenchymal markers, fibronectin, vimentin and Snail and a significant increase in 
the expression of epithelial marker, E-cadherin at the transcript level (figure 12). 
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Figure 11 – GSK3β inhibitors decrease the expression of mesenchymal markers. FOXC2 
and Fibronectin. HMLE-Snail, HMLE-Twist and Sum159 were treated with BIO, TWS119 or 
LiCl for 24 hrs and levels of β-Catenin, Fibronectin, and FOXC2 were assessed by Western 
Blot.
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In summary, the KM Plots demonstrated a correlation between the expressions of GSK3β and 
overall patient survival in TNBCs and the small molecule screen confirmed that GSK3β indeed 
could be a regulator of EMT, which is a major player in TNBC. The western blot analysis and qRT-
PCR analysis, demonstrated a decrease in the expression of mesenchymal markers and an 
increase in the expression of epithelial markers following exposure to GSK3β inhibitors 
suggesting that GSK3β could serve as a druggable target to inhibit EMT/CSC enriched TNBCs.  
 
5C. Inhibition of GSK3β decreases the migratory properties of the cells with 
mesenchymal phenotype by inhibiting the induction of EMT. 
EMT along with bestowing mesenchymal properties to the cells also enhances the migratory 
potential of the cells. GSK3β inhibitors have been known to inhibit migration of cells [227, 235, 
236]. Since our experiments demonstrated that GSK3β inhibitors inhibit the mesenchymal 
properties of the cells, this led us to investigate if GSK3β inhibitors could inhibit the migratory 
properties of the cells with mesenchymal properties. The wound healing assay was employed to 
test the efficacy of the GSK3β inhibitors in inhibiting the migratory potential of the cells with 
mesenchymal properties. HMLE-Snail cells, HMLE-Twist cells and 4T1 cells were plated for the 
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scratch assay. 4T1 cells are highly metastatic murine mammary tumor cells [237, 238]. These 
have been previously shown to have high migratory potential [237, 238]. All the cells were allowed 
to grow to confluency and a scratch was made to mimic a wound as described in experimental 
approaches. The control was treated with DMSO (0.05%) (vehicle) whereas the experimental 
cells were treated with two GSK3β inhibitors, LiCl (20mM) and TWS119 (1uM). The scratch was 
imaged at 0 hr and at regular intervals following treatment (Figure 13). Within 9hr following the 
scratch, a significant difference was observed in the ability of the treated and the untreated cells 
to close the wound. 3 images were acquired of each scratch at 0hr and at 9hr and the scratch 
was measured in 3 different spots along the wound in each image. The measurements were 
averaged to determine the distance between the wound edges. The percentage of the wound 
closed was calculated as follows 
% wound closed = (wound at 0hr - wound at 9hr)  x 100 
                              wound at 0hr 
 
The % wound closed was plotted using GraphPad Prism. The images and the graphs clearly 
demonstrate a significant decrease in the ability of the cells treated with GSK3β inhibitors to close 
the wound as compared to that of the DMSO treated cells. This observation indicates that 
exposure to GSK3β inhibitor significantly decreases the migratory potential of the cells with 
mesenchymal properties (Figure 13).  
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This observation prompted the question of whether the EMT inhibition is one of the means by 
which GSK3β inhibitors reduce the migratory potential of the cells with mesenchymal attributes. 
In order to answer this question, a modification of the scratch assay was employed as previously 
described in [208]. The cells used for the scratch assay were grown on coverslips and the scratch 
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Figure 13 –GSK3β inhibitors significantly inhibit the ability of the highly migratory cells to
close the wound. A. HMLE-Snail, HMLE-Twist, and 4T1 cells were grown to confluency,
treated with LiCl or TWS119 and a scratch was made. After 9 hours closure of the scratch
was assesses. B. Quantification of the scratch assay.
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was made on the confluent layer of cells on the coverslip. A scratch assay was performed using 
HMLE cells, which are epithelial cells and therefore do not express genes such as FOXC2 which 
are exclusively expressed in cells that display mesenchymal phenotype [60, 89]. However, it has 
been established that EMT is induced at the wound edge to facilitate the wound healing process 
[111]. Therefore, when a scratch is made in HMLE cells grown to confluence, EMT is induced at 
the wound edge to promote the closing of the wound. This has been tested in our lab previously 
and when a scratch made in HMLE cells is stained for FOXC2 after 9hrs of having made the 
scratch, FOXC2 expression was observed in the cells present at the wound edge indicating the 
induction of EMT in these cells [208]. Using this as the basis for our experimental design, we 
plated HMLE cells and allowed them to grow to confluence. A scratch was made in these cells 
and the controls were treated with DMSO (0.02%) (vehicle) and the experimental cells were 
treated with TWS119 (1uM). As expected, treatment with TWS119 decreased the ability of the 
HMLE cells to close the wound as compared to the DMSO treated cells. These coverslips were 
stained for the expression of FOXC2 and the nuclei were stained with DAPI. The DMSO-treated 
scratch showed the upregulation of FOXC2 at wound edge but there was no upregulation of 
FOXC2 at the wound edge in the scratch treated with TWS119 (Figure 14). This observation 
indicates that GSK3β inhibitors decrease the migratory properties of the cells by inhibiting the 
induction of EMT in the migrating cells. 
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5D. GSK3β inhibitors decrease the stem cell properties of mesenchymal-like 
cells. 
Cells that have undergone EMT along with exhibiting mesenchymal properties also possess more 
stem-like properties [67]. It is well established in literature that EMT and CSC properties are 
intricately linked. As GSK3β inhibitors were capable of inhibiting EMT, it was logical to investigate 
if GSK3β inhibitors were capable of inhibiting the CSC properties of these mesenchymal-like cells. 
The drugs that were shortlisted from the small molecule screen were tested for their ability to 
inhibit the CSC properties of the MDA MB 231 reporter cells. 
 
The MDA MB 231 reporter cells were counted and 1000 cells per well were plated in ultra-low 
attachment plates in the visscous mammosphere media. The control wells were treated with 
DMSO (0.05%) and the rest of the wells were appropriately treated with the 3 different 
Figure 14 – Treatment with TWS119, inhibited the expression of FOXC2 at the wound site
of HMLE cells and thereby inhibits wound healing and migration. HMLE cells were grown to
confluency, treated with TWS119 and a scratch was made. After 9 hours expression levels
of FOXC2 (red) were assessed by immunofluorescence (207).
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concentrations of all the small molecule inhibitors that were indicated to be EMT inhibitors from 
the screen. The media was replenished with the drugs every 2 days. At the end of 10 days the 
number of mammospheres formed in each well were counted and plotted using GraphPad Prism 
(Figure 15). BIO was found to be one of the drugs that were capable of inhibiting the sphere 
forming capacity of these mesenchymal-like cells (Figure 15). 
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Figure 15 – The GSK3β inhibitor BIO decreases mammosphere forming potential of
mesenchymal cells. A. MDA MB 231 reporter cells were grown in ultra-low attachments
plates in mammosphere media for 10 days. Number of mammospheres was counted and
graphed. B. The heatmap summarizes the drug screen validation using mammosphere
assay.
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As expected BIO was able to inhibit the sphere forming potential of the MDA MB 231 reporter 
cells but in order to validate this observation using multiple GSK3β inhibitors, the effect of 3 
different GSK3β inhibitors on the sphere forming potential of all the three mesenchymal-like 
human mammary cell lines, HMLE-Snail, HMLE-Twist and Sum159 was tested. The cells with 
mesenchymal phenotype were plated for mammosphere assay. The control wells were treated 
with DMSO (0.05%) and the experimental wells were treated with 3 different concentration of the 
3 GSK3β inhibitors, BIO (0uM, 0.5uM, 1uM and 2uM), LiCl (0mM, 10mM, 20mM and 30mM) and 
TWS119 (0uM, 0.5uM, 1uM and 2uM). The concentration of the drug that inhibited EMT (as 
demonstrated in section 5B) and one concentration above and below that concentration were 
used for the sphere assay. The media and the drugs were replenished every 2 days and at the 
end of 10 days the number of mammospheres in each well were counted, plotted and analyzed 
using GraphPad Prism. It was observed that all the three drugs BIO, LiCl and TWS119 were 
capable of decreasing the mammosphere forming ability of all the three mesenchymal-like cells, 
HMLE-Snail, HMLE-Twist and Sum159 (Figure 16).  
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While all the 3 GSK3β inhibitors tested were able to decrease the sphere forming ability of the 
cells with mesenchymal properties with continuous treatment over 10 days, we had observed 
earlier that GSK3β inhibitors are capable of inhibiting EMT within only 24hr of treatment. Thus, 
the question arose as to whether 24hr treatment of the cells with mesenchymal phenotype was 
sufficient to decrease their sphere forming ability, which is a surrogate assay to quantify the EMT-
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Figure 16 - GSK3β inhibitors decrease the mammosphere forming ability of the
mesenchymal cells in a dose dependent manner. HMLE Snail, HMLE Twist and Sum159
cells were grown in ultra-low attachments plates in mammosphere media for 10 days in the
presence of LiCl or TWS119. Number of mammospheres was counted and graphed.
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mediated CSC properties. To address this question, HMLE-Snail, HMLE-Twist and Sum159 cells 
were treated with BIO, LiCl and TWS119 for 24hrs. After the treatment, the viable cells were 
counted and plated for the mammosphere assay. 10 days following the plating, the 
mammospheres were quantified and plotted using GraphPad Prism.  We observed that just 24hr 
pretreatment was sufficient to significantly decrease the sphere forming ability of HMLE-Snail and 
Sum159 cells (Figure 17A). The HMLE-Twist cells seem to regain their CSC properties following 
the withdrawal of the drugs. In order to rule out the possibility, that the decrease in the 
mammosphere formation is due to the decrease in the proliferation rate of the cells following 
treatment with GSK3β inhibitors, we treated all the 3 cell lines used in this study with all the 3 
drugs and 10000 viable cells were plated in a 6-well plate. The proliferation rate of the cells 
following the withdrawal of the drugs was monitored by counting the number of cells every day 
for the next 3 days and generating a growth curve using this data (Figure 17B). We found that 
there wasn’t a significant decrease in the proliferation rate of the mesenchymal-like cells lines 
following treatment with the inhibitors as compared to the DMSO treated cells. BIO was the only 
drug which decreased the proliferation rate following treatment.  
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5E. shRNA to GSK3β decreases the CSC properties of cells with mesenchymal 
attributes. 
GSK3β inhibitors were shown to be potent inhibitors of CSC properties of cells with mesenchymal 
properties. Though multiple GSK3β inhibitors were tested for their ability to decrease the CSC 
properties of multiple mesenchymal-like cells, using biological methods to achieve the same goal 
strengthens the observations. Therefore, to examine if the biological silencing of GSK3β has the 
same effect on the stem-like properties of the mesenchymal-like cells as the GSK3β inhibitors, 
GSK3β was silenced in all the mesenchymal-like cells that have been consistently used in the 
project. HMLE-Snail, HMLE-Twist and Sum159 were transduced with the shRNA to GSK3β in the 
pGIPZ vector and the control cells were generated by transducing them with pGIPZ FF3 vector. 
The FF3 targets the firefly luciferase gene which is not expressed in the human cells and therefore 
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Figure 17 – Pretreatment with GSK3β inhibitors decreases the mammosphere forming
ability, but not proliferation of the mesenchymal cells. A. HMLE Snail, HMLE Twist and
Sum159 cells were grown in ultra-low attachments plates in mammosphere media for 10
days after 24 hr. pretreatment with BIO, LiCl and TWS119. B. Cell proliferation was
assessed by counting HMLE Snail, HMLE Twist and SUM159 cells every day fro 3 days
after drug withdrawal.
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serves as a random target control. The transduced cells were selected based on their resistance 
to puromycin and stable cell lines were generated. Protein and mRNA were extracted from these 
cells and analyzed to see if the silencing of GSK3β using shRNA was successful. 2 different 
shRNAs were used in order to rule out the possibility of off-target effects. The expression of 
GSK3β was significantly decreased in all the cell lines tested at both the transcript and the protein 
level following the transduction of the shRNA (Figure 18).  
 
The control cells and the mesenchymal-like cells with GSK3β shRNA were plated for the 
mammosphere assay. At the end of 10 days, the mammospheres were quantified and plotted 
using GraphPad Prism. As expected, suppressing GSK3β using shRNA resulted in a significant 
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decrease in the sphere forming ability of the cells with mesenchymal and CSC properties (Figure 
19). 
 
5F. GSK3β knock-out MEFs show decreased ability to form spheres. 
In addition to using shRNA, another biological means of achieving our goal is to knock out the 
gene instead of suppressing its expression. Unlike shRNA which decreases the level of protein 
expression, knocking out the gene completely eliminates the presence of the protein. A knockout 
model was therefore used to assess the effect of GSK3β on the sphere forming ability of the 
mesenchymal cells as a surrogate for CSC properties. Mouse embryonic fibroblasts (MEFs) which 
are mesenchymal cells were used for this assay. Wild-type MEFs (MEF+/+) and MEFs with 
GSK3β knocked out (MEF-/-) were obtained as a generous gift from Dr. Sarbosov at UT MD 
Anderson Cancer Center. The proliferation of the 2 cell lines was assessed. Our results indicated 
that there was no difference in the proliferation rate of the 2 cell lines. Both these cells were then 
plated for the sphere-forming assay and their stem cell potential was evaluated. It was observed 
that although there was no significant difference in the proliferation rate between the wild-type 
and GSK3β knock-out MEFs, the knock out MEFs had significantly lower ability to form spheres 
suggesting that they have reduced stem cell potential (Figure 20). 
Figure 19 – Knockdown of GSK3β decreases the mammosphere forming capability of the
mesenchymal cells. HMLE Snail, HMLE Twist, and Sum159 cells were stably transfected
with GSK3β shRNA, and grown in ultra-low attachments plates in mammosphere media for
10 days.
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5G. GSK3β inhibitors alter the CD24/44 profile of the mesenchymal-like cells 
Apart from the mammosphere assay, the proportion of the stem-like cells in the mesenchymal 
cell lines can also be determined by assessing the CD24/44 expression profile of the 
mesenchymal-like cells. CD24 and CD44 are cell surface markers that are associated with more 
differentiated state and stem-like state, respectively [67, 239, 240]. Therefore, HMLE-Snail, 
HMLE-Twist and Sum159 cells were treated with all the 3 inhibitors and the control cells were 
treated with DMSO. Following treatment, the cells were harvested and analyzed the CD24/44 
profile of the mesenchymal-like cells. Unstained mesenchymal-like cells were used to set the 
gates for CD24 and CD44 positivity. Cells with mesenchymal and stem-like properties are CD44 
positive and CD24 negative which was observed in control treated samples. However, the treated 
samples displayed a marked increase in the expression of CD24 indicating an increase in the 
proportion of the differentiated cells in the mesenchymal-like cell lines (Figure 21). 
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Figure 20 – GSK3β knockout MEFs have decreased sphere forming potential, but not
proliferation, as compared to the wildtype MEFs. A. Mouse embryonic fibroblasts (MEFs) in
which GSK3β were knocked out were grown in ultra-low attachments plates in
mammosphere media for 10 days. B. Mouse embryonic fibroblasts (MEFs) in which GSK3β
were knocked out were grown for 4 days and growth was assessed on day 2, 3, and 4.
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To summarize, we observed that BIO was one of the small molecule inhibitors selected in the 
screen that were able to inhibit the sphere forming potential of the mesenchymal-like MDA MB 
231 reporter cells. Additionally, LiCl and TWS119 were also able to inhibit the sphere-forming 
ability of the cells with mesenchymal phenotype. Further, suppressing GSK3β expression using 
shRNA and GSK3β knockout MEFs elicited the same result of a significant decrease in the 
sphere-forming potential of these cells. Examination of the CD24/44 profile of the mesenchymal-
like cells exposed to GSK3β inhibitors exhibited an increase population of CD24+ expressing cells 
indicating the inhibition of GSK3β promotes a more differentiated phenotype in the mesenchymal–
like cells. 
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Figure 21 – GSK3β inhibitors increase the CD24 positive population in mesenchymal cells.
HMLE Snail, HMLE Twist, and Sum159 cells were treated with BIO, TWS119 or LiCl, and
assessed for the presence of CD44 and CD24 by flow cytometry.
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5H. Cells with mesenchymal phenotype are more sensitive to GSK3β as 
compared to their epithelial counterparts. 
From our analyses, we observed that the effect of GSK3β overexpression on overall survival of 
patients was pronounced in the TNBCs. We also found a very significant upregulation of GSK3β 
in the Richardson 2 data set which predominantly had EMT/CSC enriched tumor samples. This 
observation suggested that there is an association between GSK3β, EMT and CSC properties 
and prompting the question of whether the mesenchymal-like cells respond differentially to the 
GSK3β inhibitors as compared to the cells with epithelial phenotype that have relatively reduced 
CSC properties. For this, we subjected a panel of cell lines to the GSK3β inhibitors. The cell lines 
selected for this assay were MCF10A cells (normal breast cell line), MCF7 (transformed epithelial 
cell line) and Sum159 (EMT/CSC enriched cell line) [241-243]. Both MCF10A and MCF7 cells 
share an epithelial phenotype whereas Sum159 cells clearly exhibit a mesenchymal phenotype 
(Figure 22A). All the cell lines were treated with a range of concentrations of BIO (0uM, 0.1uM, 
0.25uM, 0.5uM, 1uM, 2.5uM, 5uM, and 10uM), LiCl (0uM, 0.1uM, 0.5uM, 5uM, 10uM, 25uM and 
50uM) and TWS119 (0uM, 0.1uM, 1uM, 5uM, 10uM, 25uM and 50uM) to assess the dose 
response. The concentrations of the drugs were chosen such that there would be data points in 
all the parts of the dose response curve. The treated cells were then subjected to a MTT assay.  
The viability of the cells were calculated based on the absorbance of the wells treated with the 
vehicle (DMSO). The viability of the cells treated with the vehicle control was considered as 100% 
and the relative percentage viability of cells at different concentrations of the drug was calculated 
and plotted using GraphPad Prism. For all the three drugs tested, the mesenchymal-like cells, 
which possess some characteristics of basal subtype of breast cancer and TNBCs and express 
higher levels of mesenchymal markers, were found to be more susceptible to GSK3β inhibitors 
compared to their epithelial counterparts (Figure 22B). 
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In order to compare the ability of GSK3β inhibitors with other small molecule inhibitors (selected 
from the small molecule screen) to differentiate between epithelial and mesenchymal cells, we 
tested all the 11 drugs that were shortlisted from the screen. HMLE vector (a cell line with epithelial 
properties expressing the empty vector pWZL) and HMLE-Snail (a cell line with mesenchymal 
properties) were plated in 96 well plates and were treated with 6 different drug concentrations 
(0uM, 0.5uM, 1uM, 5uM, 10uM, and 100uM). The viability of the cells were assessed using the 
MTT assay and plotted using GraphPad Prism. We observed that including BIO, only PD168393 
and CP-673451 were capable of significantly differentiating between epithelial and mesenchymal 
cells. However, only BIO and CP-673451 selectively killed mesenchymal cells as compared to 
epithelial cells (Figure 23A).  
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Figure 22 – Mesenchymal cells are more sensitive to GSK3β inhibitors as compared to
epithelial cells. A. MCF10A, MCF7 and Sum159 cell morphology is shown. B. MCF10A,
MCF7 and Sum159 cells were treated with a dose range of the GSK3β inhibitors and the
viability was assessed and plotted using Graphpad.
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Figure 23 – BIO and CP-673451 selectively kill mesenchymal cells whereas PD selectively
kills epithelial cells. A. HMLE and HMLE-Snail cells were treated with a dose range of the
tested inhibitors and viability was assessed by MTT assay. B. The heatmap summarizes the
differential selectivity screen.
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PD on the other hand selectively inhibited epithelial cells as compared to mesenchymal-like cells. 
The ratio of viability of HMLE vector to HMLE-Snail was calculated and a heatmap was generated 
to summarize the findings of this experiment. When the drug selectively inhibits mesenchymal 
cells, the viability of the epithelial HMLE vector cells is high and that of the HMLE-Snail cells is 
low and the ratio calculated will be high. The color red stands for high value indicating that the 
drug is selective for mesenchymal-like cells whereas blue stands for low value indicating that the 
viability of the mesenchymal-like cells is higher. As is evident from the heatmap, BIO is capable 
of selectively inhibiting mesenchymal-like cells as compared to their epithelial counterparts 
(Figure 23B). 
 
To further test if GSK3β inhibitors can indeed differentiate between epithelial and mesenchymal-
like cells, HMLER vector control and HMLER-Snail cells were used. HMLER cells are human 
mammary epithelial cells that have been immortalized and transformed and HMLER-Snail cells 
are HMLER cells in which Snail is overexpressed and hence these cells have mesenchymal 
phenotype. The mesenchymal-like cells were labeled red. 1x106 cells of both red and green cells 
were mixed and co-cultured (Figure 24A). The cells were treated with GSK3β inhibitors and 
following treatment the proportion of viable green epithelial and red mesenchymal-like cells were 
assess using flow cytometry.  The percentage of cells was normalized to the percentage of 
red/green cells in the DMSO treated sample to account for the differences in the proliferation rate 
of the two cell lines. It was observed that there was a decrease in the proportion of the red 
mesenchymal-like cells and an increase in the proportion of the green epithelial cells indicating 
that the mesenchymal-like cells were selectively inhibited in the co-culture system (Figure 24B).          
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Summary – Aim 2: While Aim 1 established the basis of testing the potential of GSK3β inhibitors 
as targets for inhibition of EMT/CSC enriched TNBCs, observations made in experiments 
conducted to address Aim 2 indicate that GSK3β is indeed capable of inhibiting EMT and CSC 
properties both of which are hallmarks of TNBCs. The high throughput screen performed to select 
small molecules capable of inhibiting EMT in TNBC cell lines resulted in the identification of 11 
candidate drugs of which one 2, CUDC-101 and BIO were validated as inhibitors of EMT. BIO, a 
GSK3β inhibitor was selected as the lead compound as CUDC-101 has multiple different targets 
and GSK3β was established as a potential target in Aim 1. In addition to BIO, 2 other GSK3β 
inhibitors, LiCl and TWS119 were also able to inhibit EMT and EMT-endowed migratory potential 
of the EMT/CSC-enriched cell lines. Further, GSK3β inhibition using small molecules, shRNA or 
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Figure 24 – GSK3β inhibitors selectively kills mesenchymal cells. A. The schematic
demonstrates the co-culture experiment, where HMLE (epithelial cells) labeled in green and
HMLE-Snail (mesenchymal cells) labeled red were cultured together and were treated with
GSK3β inhibitors. Following the treatment the cells were harvested and subjected to FACS
analysis. B. Following treatment with GSK3β inhibitors, there were proportionally more
epithelial cells as compared to mesenchymal cells.
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GSK3β knockout in MEFs decreased the sphere-forming ability of mesenchymal-like cells. 
Moreover, drugs tested also increased the expression of CD24 surface antigen on the 
mesenchymal-like cells. We also observed that GSK3β inhibitors exerted selective inhibitory 
effect on the mesenchymal-like cells as compared to their epithelial counterparts. Thus Aim 2 
clearly demonstrates the ability of the GSK3β inhibitors to inhibit EMT and EMT-mediated 
properties in the EMT/CSC enriched cells.  
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Chapter 6 – Aim 3 – Test if GSK3β inhibitor can be effectively 
used in vivo to target CSC-enriched breast cancers. 
GSK3β inhibitor, TWS119 did not inhibit tumor size and metastatic potential of 
mesenchymal cells in vivo. 
Our observations suggested that GSK3β inhibitors were potent inhibitors of EMT and CSC 
properties in vitro, and indeed inhibition of EMT and CSC properties has been shown to decrease 
the tumorigenicity and metastatic potential of cancer cells in vivo [60]. Therefore, we used 
luciferase labelled HMLER-Snail and 4T1 cells to test if GSK3β inhibitors were capable of 
inhibiting tumorigenesis and metastasis in vivo. In both cell lines the GSK3β inhibitor TWS119 
decreases EMT and CSC properties in vitro. Both these cell lines we injected into the mammary 
fat pad of mice and were allowed to grow until a palpable tumor was observed. Once a palpable 
tumor was detected which was in ~1 week for HMLER-Snail and ~4 days for 4T1, the mice were 
randomized into 2 groups. One group was treated with vehicle (DMSO) and the other with 
30mg/Kg of TWS119 which was administered intraperitoneally every other day. TWS119 was 
used for the in vivo experimentation as it is a highly specific drug for GSK3β and the dosage and 
route of administration was decided based work of Gattinoni et.al. [244]. Tumor progression was 
monitored by imaging the mice weekly for luciferase activity (Figure 25, 26). The 4T1 experiment 
was terminated because the tumor burden exceeded the allowed size of 2 cm in diameter prior to 
the completion of the experiment. HMLER-Snail experiment had to be terminated due to scarring 
of the site of injection that made further administration of the drug difficult.  
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Figure 25 – GSK3β inhibitor TWS119 with HMLER-Snail cells in vivo. A and D. 1x106
HMLER-Snail cells were injected orthotopically and their progression in was monitored by
imaging for the luciferase signal and the luminescence was assessed. B and D. At the end
of the experiment, the animals were sacrificed and the tumors were harvested and diameter
was quantified. C and D. At the end of the experiment, the animals were sacrificed and the
lungs were harvested and nodules on the lungs were quantified.
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The animals were sacrificed and the primary mammary tumor and lungs (to check for distant 
metastasis) were isolated and fixed for immunohistochemical analysis. The tumor size was 
measured and lung nodules counted. There was no significant difference in the size of tumors 
and the number of metastatic nodules in the lungs between the vehicle-treated set and the 
TWS119-treated set in both the 4T1 and the HMLER-Snail experiments (Figures 25 B,C&D, 26 
B,C&D). This was in line with the observation that there was no significant difference in the photon 
counts between the TWS119 treated and vehicle treated mice in both these experiments (Figures 
25 A&D, 26 A&D). One of the possible reasons for the inability of TWS119 to inhibit tumorigenesis 
and metastasis, could be that the drug did not reach the tumor. In order to test this hypothesis, 
immunohistochemistry (IHC) was performed to assess the expression of β-Catenin, FOXC2 and 
fibronectin. If the drug reached the target, there would be an accumulation of β-catenin in the 
nucleus indicating active Wnt signaling and inactive GSK3β, and if the drug was able to inhibit 
EMT in vivo, the expression of FOXC2 and fibronectin would be lower in the treated tumors as 
compared to the control treated tumors. The staining showed that there was no difference in the 
expression of β-catenin, FOXC2 or fibronectin between the treated and the untreated tumors 
indication that the drug was unable to reach its target (Figure 27). 
 
Summary – Aim3: Aim3 was performed to assess the efficacy of GSK3β inhibitors to inhibit the 
tumor progression of EMT/CSC-enriched breast cancer cells in vivo. However, due to the 
concentration of the drug used or due to the chosen method of application, we observed no 
significant decrease in the tumor size and metastatic potential of the EMT/CSC-enriched HMLER-
Snail and 4T1 cells with TWS119 treatment.  
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Figure 26 – GSK3β inhibitor TWS119 with 4T1 cells in vivo. A and D. 10000 4T1 cells were
injected orthotopically and their progression in was monitored by imaging for the luciferase
signal and the luminescence was assessed. B and D. At the end of the experiment, the
animals were sacrificed and the tumors were harvested and diameter was quantified. C and
D. At the end of the experiment, the animals were sacrificed and the lungs were harvested
and nodules on the lungs were quantified.
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Figure 27 – Immunohistochemistry of xenograft tumors treated with TWS119. HMLER-Snail
tumors were fixed and immunohistochemistry was performed for β-Catenin, Fibronectin and
FOXC2. We observed no difference in the expression of these proteins between the treated
and the untreated tumors. Images were taken at 20x.
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Chapter 7 - Conclusions 
This study was performed to investigate the role of GSK3β as a potential druggable target to 
inhibit the progression of EMT/CSC-rich TNBCs. Therefore, publicly available databases were 
analyzed to determine if GSK3β is indeed upregulated in breast cancers and the analysis revealed 
that GSK3β was significantly upregulated in breast cancer tissues as compared to the normal 
mammary tissues in the Ma, Richardson 2 and TCGA datasets. Besides being expressed at 
higher levels in breast tumors, KMPlotter analysis also demonstrated that the elevated levels of 
GSK3β in TNBCs significantly correlates with worse overall survival in these patients. These 
findings suggested a possible role for GSK3β in the progression of TNBCs. 
 
TNBCs are EMT/CSC enriched cancers and as mentioned in Chapter 1, EMT and EMT-endowed 
CSCs are the cause of tumor recurrence, chemoresistance and higher metastatic potential of 
TNBCs. Therefore, inhibition of the EMT/CSC properties could be a feasible means of preventing 
TNBC-related fatality.  In order to identify small molecule inhibitors capable of inhibiting EMT in 
TNBCs, TNBC representative cell line MDA MB 231 (modified to express Zeb1 and E-cadherin 
reporter) was used to perform a high-throughput drug screen. Among the ~1300 drugs tested, 11 
drugs were identified as potential inhibitors of EMT. Upon validation using FACS, only 2 drugs 
were observed to successfully inhibit EMT in the TNBC cell line. Of the 2 drugs that were selected 
from the screen GSK3β inhibitor BIO was finalized as the lead candidate based on our analysis 
of the patient data and on the fact that CUDC-101 has multiple different targets. To rule out the 
possibility that this ability of inhibiting EMT is unique to BIO, 2 other GSK3β inhibitors, LiCl and 
TWS119 were also tested for their ability to inhibit mesenchymal properties of 3 different cell lines 
with EMT/CSC properties (HMLE-Snail, HMLE-Twist and Sum159). Both western blot analysis 
and qRT-PCR analysis demonstrated a decrease in the expression of mesenchymal markers and 
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increased expression of epithelial markers indicating an effective inhibition of EMT by the GSK3β 
inhibitors. GSK3β inhibitors were also observed to decrease the EMT-mediated migratory 
properties of the EMT/CSC-enriched cell lines (HMLE-Snail, HMLE-Twist and 4T1) and this effect 
of GSK3β inhibitors could be attributed to the inhibition of EMT at the wound edge in addition to 
the other well-established mechanisms.  
 
It is well-known that EMT bestows CSC properties on cancer cells.  As GSK3β inhibitors were 
effective in inhibiting EMT, the obvious next question was to test if GSK3β inhibitors were capable 
of inhibiting the sphere-forming potential of the TNBC cell line (MD MB 231 reporter cells). Of the 
11 drugs that were selected from the drug screen, BIO was one of the drugs capable of decreasing 
the sphere-forming ability of the TNBC cell line. Not only BIO, but the other 2 drugs LiCl and 
TWS119 and shRNA to GSK3β were also able to decrease the sphere-forming potential of the 
mesenchymal-like cells. Additionally, MEFs in which GSK3β was knocked out also lost their ability 
to form spheres. Further, the 3 GSK3β inhibitors tested were also able to increase the proportion 
of CD24 expressing cells in the mesenchymal-like cell lines. All these observations taken together 
indicate that GSK3β inhibitors decrease the CSC properties and increase the proportion of 
differentiated population of the mesenchymal-like cell lines. 
 
As the GSK3β inhibitors were shown to inhibit EMT and EMT-mediated CSC properties, which 
are characteristic of the mesenchymal-like cell lines, it was intriguing to test if the GSK3β inhibitors 
exerted selective inhibitory effect on EMT/CSC enriched cells as compared to their epithelial 
counterparts. Of the 11 drugs isolated in the screen, BIO was one of the 2 drugs capable of more 
potently inhibiting mesenchymal-like HMLE-Snail cells as compared to the epithelial HMLE-vector 
cells. All 3 GSK3β inhibitors (BIO, LiCl and TWS119) selectively inhibited mesenchymal-like cells 
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(Sum159) as compared to epithelial (MCF7) or normal-like (MCF10A) breast cell lines. In addition, 
in co-culture experiments, all 3 GSK3β inhibitors selectively inhibited mesenchymal-like (HMLER-
Snail) cells as compared to the epithelial (HMLER) cells.  
 
Based on our in vitro observations that GSK3β inhibitors effectively inhibited EMT, and EMT-
mediated enhanced migratory and sphere-forming potential and selectively inhibited 
mesenchymal-like cells, we decided to test GSK3β-specific inhibitor (TWS119) in vivo. However, 
at the dosage used and with the route used to administer the drugs, no inhibitory effect was 
observed on the tumor size and metastatic potential of EMT/CSC-enriched cell lines. IHC analysis 
indicated that there was no inhibition of GSK3β based on the observation that there was no 
difference in the level of expression and localization of β-catenin between the treated and the 
untreated tumors. Therefore, the drug dosage and administration has to be modified to ensure 
that the drug is able to effectively inhibit GSK3β in vivo. 
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Chapter 8 – Discussion and future directions 
Since the discovery of Wnt signaling and its role in cancer, there has been an extraordinary 
emphasis on the association of the Wnt signaling with EMT, CSC properties and consequently on 
metastasis of cancers. However, this eclipses the roles played by other equally important players 
in the field. In this study we focused on the role of GSK3β and its importance as a prognostic 
factor and therapeutic target in breast cancer. 
 
In our study, we found that high expression of GSK3β correlated with the poor survival of breast 
cancer patients. This was surprising as GSK3β is a negative regulator of Wnt signaling and 
therefore the presence of high levels of GSK3β would indicate an inactive Wnt signaling which 
would be considered as a good prognostic factor, considering the known effect of Wnt signaling 
on CSCs. Data mining also revealed that GSK3β is indeed expressed in elevated levels in breast 
tumor samples as compared to normal breast tissue.  
 
Using multiple small molecule inhibitors of GSK3β, we have demonstrated that inhibition of 
GSK3β significantly decreased the expression of FOXC2 and fibronectin, both of which are robust 
markers of the mesenchymal phenotype. The decrease in expression of FOXC2 protein clearly 
explains the loss of CSC properties in the mesenchymal-like cells, as it has been previously 
illustrated that FOXC2 is essential for the CSC properties of cancer cells [67]. Additionally, under 
certain circumstances, GSK3β is known to be a positive regulator of NFκB, which in turn, has 
been demonstrated to promote FOXC2 expression and function [245, 246]. Therefore, 
pharmacological inhibition of GSK3β also promises to downregulate NFκB-mediated upregulation 
of FOXC2, thereby providing the means of targeting multiple pathways of tumor progression and 
metastasis [208]. In depth understanding of how GSK3β functions and is regulated sheds light on 
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how complex this protein is. For example, when we treat with a small molecule inhibitor, there is 
no way of pinpointing the pool of GSK3β that is majorly affected or if the overall function of GSK3β 
in all the pools is uniformly inhibited. There is also a dearth of knowledge regarding the flux of 
GSK3β between the different pools. Therefore, it is impossible to predict if one pool of GSK3β is 
maintained at the cost of the other pools thus allowing certain functions of GSK3β to proceed 
uninterrupted while compromising on the functions that are less vital to the cell in a particular 
context. Therefore, while it is easy to just examine the role of a molecule with regard to a single 
signaling pathway or cell type, looking at the bigger picture is essential to give context to the 
findings.  
 
Again contrary to the expectations, we found that inhibition of GSK3β clearly inhibited the CSC 
properties of the mesenchymal-like cells, which is evident in both the increase in the expression 
of differentiation-related cell surface marker CD24 and the decrease in the stem cell-related 
sphere forming ability of the cells. This emphasizes the fact that these effects of GSK3β inhibition 
could be due to the effect of the inhibitors on the Wnt-independent activity of the GSK3β. GSK3β 
is a highly versatile kinase with several targets involved in different pathways which regulate each 
other and thus making GSK3β a pivotal player in regulating the different pathways. Therefore, the 
effect elicited by GSK3β inhibitors need not primarily be equivalent to the activation of Wnt 
signaling pathway. The different pathways that could be affected depend upon the regulation of 
the downstream molecules which determine the direction of flow of information.  
 
Along with the inhibition of the CSC properties, the GSK3β inhibitors also significantly decrease 
the migration of the mesenchymal-like cells, which indicates a reduction in the aggressive 
metastatic potential of these cells. There have been other publications demonstrating that 
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inhibition of GSK3β inhibits the migratory properties of the cells and this effect of GSK3β has been 
attributed to its effects on molecules such as Rac and Rock [236]. However, we show additional 
means by which GSK3β could alter the migration of the cells. In HMLE cells, we show that 
migration of the cells is accompanied by the upregulation of FOXC2 at the migratory front of the 
cells. In the presence of the GSK3β inhibitors, this upregulation of FOXC2 is prevented which 
adds to the inhibitory effect of GSK3β inhibitors. 
 
One of the main challenges in this study was the fact that shRNAs to GSK3β were not able to 
recapitulate the downregulation of mesenchymal markers effected by the small molecule 
inhibitors. This could be attributed to the fact the small molecule inhibitors inhibit GSK3β to a 
greater extent than the inhibition by the shRNA, and that the inhibition by the shRNA was enough 
to affect the sphere forming ability of the cells, but not sufficient to suppress the expression of the 
mesenchymal markers. In order to address this issue, GSK3β knockout MEFs were used and we 
were able to demonstrate a decrease in the expression of FOXC2, but it was difficult to use 
fibroblasts to study alterations in EMT. Another means of testing could be to use CRISPR 
technology to delete GSK3β which would be superior because it would deletion of the GSK3β 
gene resulting in the abrogation of the protein. We have not yet tested this approach. While both 
knockdown of GSK3β as in the MEF and the use of CRISPR are good means for identifying the 
role of GSK3β in cell lines, this method will be hard to achieve in patients. Also GSK3β is a 
multifunctional molecule with many reported (apparently unrelated) functions. Another 
explanation for this discrepancy could be the fact that the small molecule inhibitors inhibit both 
GSK3β and GSK3α, which have some redundant functions. However, attempts to create double 
knockdowns failed as cells most likely did not survive in the absence of such vital kinases. It is 
interesting to note that shRNA to GSK3β did significantly decrease the CSC properties of the cells 
without affecting their EMT properties. This leads to another interesting theory that GSK3β could 
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be the point of bifurcation between EMT and CSC properties which are currently considered to 
be the 2 sides of the same coin. The ultimate goal of this study is to find a means of targeting 
tumor progression and metastasis. Due to the importance of Wnt signaling in tumor progression 
and metastasis, efforts are ongoing to design Wnt inhibitors that can effectively inhibit metastasis. 
However, these studies are in their infancy and have to overcome several obstacles to be 
successful anticancer drugs.  
 
The most striking finding in this study is that the GSK3β inhibitors have a potent inhibitory effect 
on mesenchymal-like cells (Sum159) but not on epithelial (MCF7) or normal-like (MCF10A) breast 
cancer cell lines. It will be important for future studies to decipher the molecular mechanism 
underlying this differential activity. One way to address this issue would be to perform a microarray 
to compare the changes in the gene expression profile of the cells following treatment with GSK3β 
inhibitors. This could provide insight into which pathways are differentially altered between the 
normal-like, epithelial and mesenchymal-like breast cancer cell lines.  
 
On the other hand the GSK3β inhibitors have been widely used in the treatment of psychiatric 
disorders and their effect and side effects have been well documented. GSK3β is a vital molecule 
that serves as a hub for several signaling pathways. Therefore, the small molecule inhibitors of 
GSK3β can be used to efficiently target and modulate several different pathways and significantly 
hinder the proliferation and metastasis of cancer cells. Despite the existence of controversial 
literature suggesting a potential role of GSK3β as a tumor suppressor in breast cancer based on 
in vitro studies, there is paucity of in vivo data to substantiate this claim [192, 247, 248]. Knowing 
how diverse and heterogeneous cancer is, even breast cancer cannot be classified as a single 
disease. Therefore, it would be unwise to classify a ubiquitous and multifunctional kinase such as 
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GSK3β as a tumor promoter or suppressor. Additionally the strong correlation between the 
expression of GSK3β and poor prognosis in breast cancer patients is in itself a strong proponent 
of the therapeutic use of GSK3β inhibitors in addition to the standard-of-care treatment currently 
available for the treatment of breast cancers. One of the other main concerns is that inhibition of 
GSK3β in patients would lead to the activation of Wnt, a tumor promoter and hyperactivation of 
Wnt signaling pathway in breast cancer is a well-established fact. Therefore, inhibition of GSK3β 
cannot further activate the already activated system. Therefore, treating breast cancers with 
hyperactivated Wnt signaling should manifest no effect on the Wnt signaling pathway but on the 
other pathways in which GSK3β is involved. There are also reports to show that there is no 
evidence of increased tumor incidence in patients chronically treated with lithium for their 
psychiatric disorders [249]. 
 
Contrary to expectation, our in vivo experiments to test the efficacy of the GSK3β inhibitors were 
not conclusive regarding the efficacy of the drug. It is possible that the injected drug did not reach 
the intended target. Therefore, we performed IHC to test if this hypothesis is true. The tumors and 
the lungs isolated from the animals were fixed and embedded and stained to determine if GSK3β 
was indeed inhibited in the tumors or if the drugs did not reach the target. The HMLER-Snail tumor 
sections were stained for β-Catenin, FOXC2 and fibronectin. If the drug successfully reached the 
target and inhibited GSK3β, we would expect to see a significant increase in the expression and 
nuclear localization of β-Catenin and based on the in vivo experiments, a decrease in the 
expression of FOXC2 and fibronectin. However, we observed no difference in the levels of 
expression of β-Catenin between the GSK3β inhibitor treated and the control treated tumors 
indicating that the drug did not reach its target or did not exert its effect on the tumor cells. 
Therefore, the experiment did not give the expected results. Additionally, our observations with 
regards to the 4T1 experiment indicate that continued treatment could have attenuated the ability 
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of the breast cancer cells to metastasize. However, this could not be tested due to the morbid 
tumor volumes in case of 4T1 cell lines and due to the toxic effect of DMSO at the site of injection. 
 
One of the main challenges is the lack of in vivo studies using TWS119. As a result, there is not 
enough published data available to determine the correct dosage and treatment regime. 
Therefore, more pharmacological studies are required to optimize the treatment plan for testing 
the efficacy of the drug to inhibit tumorigenesis and metastasis of breast cancer. Considering the 
ability of GSK3β inhibitors to specifically target mesenchymal-like cells with CSC properties, the 
GSK3β inhibitors may be better suited for combination treatments. 
 
A key future direction is to identify chemotherapeutic agents whose efficacy can be improved by 
the addition of GSK3β inhibitors to the treatment regimen. As the GSK3β inhibitor from Eli Lily 
(LY2090314) is FDA approved and in clinical trial, we have decided to add this drug to our studies 
[200]. LY2090314 has been shown to increase the potency of platinum drugs [200]. Therefore, 
platinum drugs will be one of the primary candidates to be tested for combination treatment with 
GSK3β inhibitors in TNBCs.  The next step will be to determine the dosage and test the efficacy 
of the drug in vivo. In case of LY2090314, there have been several in vivo studies performed in 
melanoma models [250]. Therefore as the treatment parameters have been well established, it 
could therefore serve as the starting platform to test this drug in vivo.  Based on these new data, 
we aim to design combination treatment regimens for treating orthotopic TNBC mouse models. 
Additionally, we have access to several TNBC patient-derived xenograft (PDX) models through 
our collaborators and these will serve as perfect models to test the combination treatments as 
they are truer representatives of the disease heterogeneity than cell lines. The subsequent goal 
would be to study the pathways that are differentially altered between the epithelial and 
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mesenchymal-like cells following treatment with GSK3β inhibitors using microarray or RNAseq 
techniques.  
 
The primary goal of this study was to identify novel druggable targets to treat TNBCs which 
currently lack targeted therapies. This study serves as a preliminary indicator that there is more 
promise in using GSK3β inhibitors if close consideration is given to the pleiotropic signaling 
cascades it influences rather than as a mere modulator of a single signaling cascade which is the 
Wnt signaling pathway. Our goal is to continue our efforts to establish a probable mechanism of 
action for the effect to GSK3β inhibitors in the inhibition of EMT and CSCs and to define a viable 
and potent combination treatment for TNBCs. 
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